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Abstract 
 Lyophilization is a common method used for long term stability of 
pharmaceutical and biopharmaceutical products that are unstable in the liquid 
state for a substantial period of time. Currently, formulation and cycle 
development are often determined empirically. Although this approach is 
gradually changing as scientific publications reveal more about the nature of 
protein stability, nevertheless the lack of material during early stage development 
prevents large screening investigations to identify optimum formulations. 
 
 The use of high throughput methods coupled with factorially designed 
experiments enables a far more efficient and wider screening and optimisation of 
viable formulations for development. This thesis explores the use of micro titre 
plates for formulation development with emphasis on formulations for 
lyophilization. This is coupled with design of experiment methods to provide a 
powerful engineering tool for the formulation scientist. 
 
 While much has been done to model freeze drying cycles and optimize 
cycle parameters, current models are generic and require system specific data 
which can be hard to collect. By applying design of experiment principles, a 
system specific model was developed to allow the optimisation of cycle 
development to identify key parameters and produce a product that would meet 
critical quality attributes. Such a platform would lend itself well to quality by 
design and its application in lyophilization development. 
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Chapter 1.  Introduction 
 
Lyophilization involves the freezing, sublimation and subsequent 
desorption of a solvent from a product to result in a material that is dry, stable and 
readily soluble. In fact the term lyophilization comes from the word lyophile 
which means “solvent loving.”(1). The principle of lyophilization or freeze drying 
dates back to early Incas in South America who would freeze their potato or meat 
on the low lying plains overnight then carry the produce up the hills in the higher 
altitude where the low pressure induced the sublimation of ice and resulted in a 
freeze dried product (2). Although no-one can claim to have invented the first 
freeze dryer, there are records which suggest that Nestle produced freeze dried 
coffee as early as 1938. The first commercial freeze-dried biological product was 
blood plasma for the troops during WW2 (3). With the current high value of the 
biopharmaceuticals market and the prediction for further growth (4) there is a high 
demand for well formulated biopharmaceutical products. 
 
1.1 Solid State Formulation  
In an industrial process the ideal product ready for shipping should be 
stable with a shelf life of at least two years. It should be in its dosage size ready 
for use by the end user. Therefore the optimum formulation would be a liquid. 
Furthermore, the product is generally in liquid state following final stage 
polishing and a liquid final formulation would require minimal further processing 
(each process step costs money, takes time and often incurs product losses). 
However for protein based biopharmaceutical products in particular, liquid 
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formulations tend to be unstable at ambient conditions. It is important to 
remember that the product can be exposed to a wide range of conditions during 
shipping such as low pressure and cold temperatures in an airplane or high 
temperatures and rough handling or agitation on a truck travelling through Africa 
(5). 
 
During storage in liquid formulations proteins are mobile and free to 
interact with each other and with the other components of the formulation. There 
are many degradation pathways through which biopharmaceuticals can lose 
biological activity and they can be grouped into chemical instabilities and 
physical instabilities (6). Chemical instabilities include deamidation, oxidation or 
hydrolysis among others while physical instabilities include denaturation, 
adsorption, aggregation and precipitation. Furthermore the stability of a 
biopharmaceutical product can also be dependent on the final protein 
concentration in the dose. High concentrations can encourage aggregation, 
whereas at low concentrations, surface adsorption losses can become problematic. 
As biopharmaceuticals become more complex there exists a need to preserve them 
in a stable state that prevents degradation during storage. This need highlights a 
requirement for solid state formulations. 
 
Biopharmaceuticals can be stored as a solid through four methods: 
freezing, crystallization, spray drying and lyophilization.  
 
Freezing is often used in the laboratory for storing and preserving proteins. 
However the freeze thaw cycle used has to be optimized to prevent protein 
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degradation. The freezing itself can damage the protein and most importantly this 
method requires the use of a freezer for storage and transportation. As such, while 
it is often used as an intermediate step during bioprocessing at two different sites 
where it can be further purified to remove aggregates, it is not feasible for 
biopharmaceutical production as a final dosage form. 
 
Precipitation is a process by which the product is “salted out” of solution 
in a well defined buffer and ionic strength resulting in a precipitated product. This 
is carried out in a stirred tank and the solution is then centrifuged to extricate the 
product.  It is relatively cheap requiring little in the way of equipment as 
centrifuges and stirred tanks are often already present in production facilities. 
Antibiotics are an example of a product that is produced through this method. 
However, in relation to protein based products this method is essentially reliant on 
precipitation of proteins to form an insoluble precipitate. If the precipitate can be 
re-dissolved easily and the proteins themselves refold to their native state, then 
precipitation may be a viable option. In general though complex proteins do not 
lend themselves well to reversible precipitation and this is not a viable option. 
 
Spray drying is a common process in both the healthcare and the food 
industries. A concentrated product stream is forced out of a nozzle at high 
pressure where a blast of hot air strips away the water layer around the droplets 
resulting in a fine dried powder. Although the hot air can damage heat labile 
proteins, the speed of the process means that this is not the primary factor that 
results in protein degradation (7). Rather the high level of water/air interfaces 
resulting from the high surface area of multiple droplets results in degradation of 
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the protein at high levels (6, 7). Furthermore the proteins are subject to high shear 
rates in the proximity of the nozzle and these are known to damage proteins (8). 
 
An alternative to spray drying is spray freeze drying where the product 
stream is brought into contact with a medium such as liquid nitrogen and the 
frozen droplets are then dried under vacuum or a fluidized bed or a combination 
of both (11, 12). This process has been used to develop powders for inhalation as 
the porous powder particles produced re – suspend well in the respiratory tract. 
However, for production of single dose vials containing a dry drug product where 
the filling, drying and finishing all takes place in one sterile step, lyophilization 
can be a better option. 
 
Lyophilization is a gentle process by which a protein is first immobilized 
in a solid ice structure and then dried under vacuum. If a product is stable or 
robust enough that one can produce a stable final stage product for the customer 
using any of the other methods then freeze drying should not be the formulation 
process of choice. Lyophilization is an expensive procedure as it involves a high 
capital cost investing in a vacuum chamber and an accurate freezing shelf and 
high running costs as it involves vacuums, low temperatures and time. 
Furthermore lyophilisation processes are usually run in a batch rather than 
continuous mode. Batch methods tend to cost more than continuous ones such as 
spray drying. It also means that all ones “eggs” are essentially in one basket and if 
the run should fail an entire production batch is lost. As such it is important to 
bear in mind when designing a process that lyophilization is often the last resort 
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approach to solid state formulation. However the delicate nature of proteins means 
that this last resort is often required. 
1.2 Equipment 
The lyophilizer itself is a fairly simple piece of equipment that has been 
unchanged in principle since its first use. A systematic diagram of a lyophilizer is 
shown in Figure 1.1. Some developments that have been made in the past twenty 
years or so are more airtight chambers, automatable systems programmed using a 
PC interface including data monitoring, sterilisable chambers and better vacuum 
pumps.  
 
Figure 1.1 Schematic of freeze drier with vial of product on shelf 
The product can be pre-frozen or frozen in situ, and thermocouples can be 
inserted into some vials to monitor the freezing rate. Once all the vials are frozen 
the vacuum pump is switched on and the pressure is lowered. Ice sublimes to 
vapour and is transported to the condenser which is kept at a much lower 
temperature than the drying chamber. The ice condenses on the walls of the 
condenser thereby preventing the vapour from contaminating the vacuum pump. 
The vial can be partially stoppered and following secondary drying, the stopper 
can be pressed into the vial thereby sealing the product in a dry environment. 
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Although the pressure within the vial is lower than atmospheric pressure, this is 
not a problem in fact it is preferred as it will then suck in the water from a syringe 
inserted for resuspension and delivery to a patient. 
 
1.3 The Freeze Drying Process 
When detailing the lyophilization process it is common to break it down 
into its component stages: freezing, primary drying and secondary drying. 
1.3.1 Freezing Phase 
The freezing stage involves freezing the product in containers until the 
solution changes from liquid to a solid state. The solvent, generally water, forms 
ice crystals with the protein and any other components squeezed into the 
interstitial space between the crystals. The rate at which the shelf temperature is 
lowered is critical in determining the crystal size. Rapid cooling rates typically 
result in small crystals whereas slow cooling rates result in large crystal 
formation. There is a trade off to consider as larger crystals can impose higher 
mechanical stresses on the protein structure while the high surface area of small 
crystals increases the size of the ice water interface and such interfaces are known 
to damage proteins (6, 11). From an engineering perspective, larger crystals mean 
larger pore sizes forming during the primary drying phase. This means the rate of 
flow of vapour from the ice front through the dried layer can proceed at a faster 
pace with some reports of an increase of up to 3.5 times the initial primary drying 
rate (12).  
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The challenge during freezing is to ensure the product freezes. As obvious 
as this may sound it cannot be taken for granted as ice nucleation is a random 
process that cannot be engineered easily. As mentioned previously, the frozen 
product is a mixture of crystalline ice and amorphous/glassy regions containing 
the protein in the interstitial spaces. In order to ensure all material is solid one has 
to bring the temperature down below the glass transition temperature otherwise 
known as the Tg’. Even at this temperature ice nucleation rather than super – 
cooled liquid is not a certainty and the purer the solution and the more perfect the 
surface of the container, the lower the chances of nucleation. While attempts have 
been made to force the solution to nucleate through mechanically shaking the 
containers in some way, no viable method exists today on an industrial scale. This 
means that in the case of biopharmaceuticals where the product is lyophilized in 
vials, ampoules or syringes, each individual container will freeze at a different 
time and one will have heterogeneous nucleation between the containers 
Furthermore, ice crystal growth continues during freezing, so containers that 
freeze early will have larger crystals compared to those that freeze later. 
 
A solution to the problem of heterogeneity is through the use of 
annealing(12, 13). During annealing the shelf temperature is increased to about 
10-20oC above the Tg’ after freezing and held for a period of time. This allows the 
crystals to grow. As this process is controllable, one can improve the quality by 
design of the systems by using an annealing step that results in a more defined 
crystal size in all vessels. 
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The Tg’ of the formulation is a crucial characteristic when designing a 
lyophilization cycle. In fact in the past many cycles were designed purely on the 
knowledge of the Tg’. There are several analytical methods for determining the Tg 
and these are discussed under section 1.6 Formulation characterization. 
   
1.3.2 Primary Drying Stage 
During this phase the pressure in the chamber is lowered to create a 
pressure difference between the vapour pressure directly above the ice front and 
the chamber. The process of sublimation of ice at low temperature and low 
pressure can easily be visualized using the phase diagram shown in Figure 1.2. At 
sub zero temperatures below 6.1 millibars the solid ice will sublime to vapour.  
 
Figure 1.2 Phase diagram for water 
The sublimation process requires energy the source of which is the heated 
shelf. It is essential throughout the process that the temperature of the contents of 
the container do not exceed the Tg’ throughout otherwise meltback can occur. 
However, by carefully adjusting the shelf temperature one can provide maximum 
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thermal energy while maintaining a product temperature below its Tg’. Overall 
this process can be described as a heat and mass transfer process. The mass 
transfer is driven by the difference in pressures between the vapour pressure and 
the chamber pressure. However, the vapour pressure is dependant on the product 
temperature which will drop as the ice sublimes unless sufficient heat transfer 
from the shelf to the product occurs to replace the loss of energy due to enthalpy 
of sublimation. 
 
The rate of vapour flow from the drying chamber to the condenser is 
dependant on the respective vapour pressures in each chamber. However as the 
condenser is generally kept at a much lower temperature than the drying chamber, 
the water vapour condenses back to ice on the coils of the condenser resulting in a 
far lower vapour pressure in the condenser than the drying chamber. Although in 
theory by changing the temperature in the condenser one could alter the vapour 
pressure in the condenser, the pressure in the condenser is likely to remain the 
same as the chamber pressure due to the vacuum pump to which the condenser is 
attached. In the event the operator raises the condenser temperature thereby 
raising the vapour pressure in the condenser, this would result in vapour flow into 
the vacuum pump. As such, the condenser temperature is not seen to be a driving 
factor during freeze drying. 
 
Because the driving force behind primary drying is a pressure difference, it 
is logical to conclude that the greater the number of ice particles at the ice/air 
interface, the greater the number of particles are subject to the pressure difference 
and therefore the greater the rate of primary drying. From an engineering 
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perspective this means that one should aim to have a low aspect ratio between fill 
depth and surface area. It is better to have a large diameter vial filled to a depth of 
4mm than a small diameter vial filled to a depth of 20mm. 
 
It has been shown that there are three factors that resist mass transfer from 
container to condenser: a) the dried product layer that forms on top of the ice 
front; b) the container stopper if present; and c) the chamber resistance (14). The 
chamber resistance is generally the result of the interconnecting tube between the 
product chamber and the condenser. While at aggressive drying rates the 
chamber-condenser pathway can become an issue to the point where the vapour is 
travelling at mach 1 (18). Pikal et al (15) found that the dominant resistance 
accounting for nearly 90% of resistance was due to the dried – product layer. In 
light of this it is easy to understand why large ice crystals resulting in large pore 
sizes are important to increase the rate of primary drying.  
 
Heat transfer generally takes place through three mechanisms: conduction, 
convection and radiation. Conduction is the flow of energy through molecular 
vibration. If we assume a slab of surface area A and thickness x as shown in 
Figure 1.3, 
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Figure 1.3 Heat flow across a finite slab 
then the equation for heat flux via conduction through the slab can be described as 
follows: 
€ 
dQ
dt = AkxΔT 	  
Equation 1.1 Conduction heat flow equation for a slab where Q is energy, t is 
time, A is surface area, k is thermal heat transfer coefficient, x is the wall 
thickness and ΔT is the temperature difference between one side of the slab 
and the other (T2-T1 where T2>T1) 
Convection relies on molecules carrying thermal energy from a source to a 
material, in this case from the shelf to the product via the bottom of the vial. Due 
to the low pressures involved in primary drying, there is a lack of molecules 
present to carry this out. As such the convection is not a major contributor to heat 
transfer during primary drying but must not be ignored. The primary method of 
heat transfer is through conduction, namely from the shelf through the container 
walls and then to the product.  
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Radiation does occur although when freeze drying biopharmaceuticals, 
conduction is by far the dominant factor. In food manufacture, heat transfer is 
often via radiation. Radiation occurs via infra – red and occurs between all bodies. 
The heat radiative heat flux from a source of thermal radiation can be described 
by Equation 1.2. 
€ 
q = εσAT 4  
Equation 1.2 Stefan – Boltzmann Law for thermal radiation where q is heat 
transfer per unit time (W), ε  is the emissivity (between 0 and 1), σ  is the 
Stefan – Boltzman Constant (5.6703 x 10-8 wm-2K-4), T is the absolute 
temperature (K) and A is the surface area (m2) 
 
Although in biopharmaceutical manufacture, conduction is the dominant 
mechanism, it is important not to underestimate the radiative effects from vial to 
vial and from the chamber door. Doors of laboratory and pilot scale freeze driers 
are often transparent and the containers closer to the door in these devices can dry 
faster than those towards the back. Similarly, containers on the edge of the shelf 
can have different drying rates from containers in the centre of the shelf (16). 
 
Although the drying stage as a whole can be split into two distinct stages 
separated by their mechanisms (sublimation and diffusion), during the actual 
process it is not possible to determine when one stage stops and the other begins 
as there is a great degree of overlap between the two due to the heterogeneity 
formed in the sample. Secondary drying can occur during the primary drying 
phase. The distinction between the two is governed by the origin of the water 
vapour. In primary drying the vapour source is the ice crystal whereas during 
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secondary drying the water vapour is from the water molecules adsorbed onto the 
surface of the cake. 
 
1.3.3 Secondary Drying Stage 
As stated above, this step involves the desorption of the water molecules 
from the cake structure. In extreme cases this can also involve the removal of 
bound water from the protein super structure. This is done by raising the 
temperature of the product giving the ice molecules energy to sublime and diffuse 
through the cake structure. It is important to note that following primary drying, 
the Tg of the product is now above zero so the shelf temperature can be raised 
sometimes as high as 50 oC without melting the product. While the low pressure 
must be maintained, there is little to gain from extremely low pressures as 
temperature is the determining factor for the rate of secondary drying. 
 
Although the Tg of the product is generally above zero after primary 
drying, the presence of up to about 25% moisture means the Tg can be around 
room temperature. As the whole purpose of lyophilization is to produce a material 
that is stable for long term storage at ambient conditions, this is unacceptable as 
the product is likely to melt or collapse during storage at room temperature. Hence 
the need for a secondary drying process. Also the presence of water in the 
amorphous stage could allow the protein to remain sufficiently mobile to degrade 
by the various chemical mechanisms mentioned earlier. 
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1.4 Container systems 
Several container systems exist for industrial lyophilization such as trays, 
syringes, vials and ampoules. In general, bulk freeze – drying trays are often used 
for low value products such as food or during intermediate processing steps (17). 
Traditionally products were most frequently lyophilized in vials which were then 
stoppered at the end of the run (18). Ampoules which are essentially glass sealed 
vials are used in some areas as the storage properties are superior (19), however as 
the vast majority of lyophilized biopharmaceuticals are for injection, the use of 
syringes is gaining growing popularity as it offers the most convenience for the 
end user (20-22). Furthermore, if the product is going to be placed in a syringe 
anyway, the vial is a wasteful method of storage. For the purposes of all 
investigations in this thesis, the container system is a vial unless otherwise 
specified. 
 
1.5 Formulation 
A typical formulation for a biopharmaceutical will consist of five 
components: 
A solvent 
The active pharmaceutical ingredient (API) 
Bulking agent 
Cryoprotectant 
Lyoprotectant 
 
It is possible and indeed quite common for one species to act as two agents 
such as mannitol which can act as a bulking agent and cryoprotectant. If it is 
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possible to freeze dry a product without the use of bulking agents, cryoprotectants 
and lyoprotectants, then there is no need to include them. However the majority of 
biopharmaceuticals require them to lyophilize. If the API and the buffer together 
make up less than about 2% solids the product will not form an elegant cake 
structure and can blow out from the top of the vial. Furthermore, the resultant 
cake must be well formed, readily soluble and not show evidence of shrinkage.  
 
The typical solvent is water. This is partly because many organic solvents 
can damage proteins but also because the bioprocess associated with the product 
is generally conducted in the aqueous phase with water as the solvent. There is an 
advantage to using solvents with higher volatility than water as they will sublime 
under lower pressures during primary drying. However, this is tempered by the 
fact that often such solvents will have far lower melting points requiring lower 
shelf temperatures. Some therapeutic molecules are more easily dissolved in 
solvent than water and t-butyl alcohol is an example of an alternative non - 
aqueous solvent (23). 
  
The water will in nearly all cases contain a buffer. Buffers are used when 
working with proteins to prevent unwanted pH shifts that can cause proteins to 
denature and/or aggregate. This is important in lyophilization as freeze 
concentration effects caused as the water forms into crystals and the remaining 
materials are forced into the amorphous regions can be quite dramatic. However, 
the buffer must be picked with care as it is known that some buffers (e.g. 
Phosphate Buffer) shift pH when frozen which can be detrimental to the process. 
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There is little one can do about the API as the dosage size for the end user 
of the product is predetermined and cannot be altered. Concentration can be an 
issue as at high concentrations of protein, the freeze concentration effect which 
can occur during the freezing stage can force a layer of protein to form a skin on 
the surface of the frozen product. During the sublimation stage this skin can resist 
mass transport until the pressure build up under the skin is high enough to blow 
the skin apart, perhaps out of the vial and definitely resulting in a collapsed cake 
structure. Should this be an issue, for example where the dosage size requires a 
high concentration of protein which will not lyophilize, it may be possible to 
lyophilize at a low concentration but high volume and then resuspend with a low 
volume to result in the required concentration. Otherwise there is very little the 
process designer can do about quantity and concentration of API in the vial. 
 
The use of bulking agents is fairly common in situations where the solid 
content within the formulation is too low to form a cake. In such situations, 
without the use of a bulking agent, a small quantity of fine powder will form 
which could potentially blow out from the top of the vial. Even if it does not, the 
end user prefers a visually appealing cake structure which can necessitate the use 
of a bulking agent. A common example of a bulking agent is mannitol. An 
advantage of mannitol is its ability to crystallize if frozen slowly thereby 
providing a scaffold for the API. However if frozen too rapidly to crystallize the 
mannitol can expand during primary drying and break the vial (24-27).  
 
As explained earlier, the freezing process exposes the protein ingredient to 
high mechanical stresses as the crystals form and the proteins are forced into the 
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interstitial spaces between the crystals. Furthermore pH shifts which may be 
occurring, the freeze concentration of salts present in the formulation or buffer are 
all properties that can chemically denature the protein structure. Therefore, there 
is a requirement for preservative materials called cryoprotectants. Examples of 
cryoprotectants include surfactants or polymers (5). Similarly, to protect the 
protein shell during lyophilization the use of lyoprotectants prevents denaturation 
of the protein. Various mechanisms have been proposed for the method by which 
lyoprotectants preserve protein structure, for example by preferentially hydrogen 
bonding to the protein in place of water. In any event, non – reducing 
disaccharides are generally the lyoprotectant of choice (5). 
 
The process by which suitable cryo- and lyo- protectants are selected is 
often empirical in nature and contributes to the labelling of lyophilization as a 
“dark art.” While the use of solid scientific understanding to develop a solution is 
always preferred the current knowledge regarding how these excipients interact 
with proteins and the mechanisms by which they protect the protein is still fairly 
limited. As such, a different approach is required that can allow a systematic 
engineering procedure to identify optimum formulations. 
 
1.6 Formulation characterization  
Formulation characterization includes developing an understanding of the 
interaction between the formulation and the API, optimizing pH, ionic strengths 
etc. In terms of developing the lyophilization cycle formulation characterization 
generally refers to thermal analysis of the formulation. An understanding of the 
thermal properties of a formulation is vital to provide scientific logic behind the 
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process design stage (28, 29). The key thermal characteristic necessary depends 
on whether the material crystallizes on freezing or not. In the event it crystallizes 
then it is necessary to obtain the eutectic point, the temperature at which the 
material changes from a liquid to a crystalline solid otherwise known as Teut 
whereas an amorphous material changes to a glass hence the term glass transition 
point written at the Tg’. The equipment used for determining these points are 
identical for both crystalline and amorphous materials with the exception of the 
freeze dry microscope which is only applicable to crystalline materials. 
 
1.6.1 Differential Thermal Analysis (DTA), Resistance and Impedance 
measurement 
Eutectic meters are devices that take measurements to identify Teu. 
Examples of such devices are the Lyotherm 1 and Lyotherm 2 (Biopharma 
Technology Ltd, Winchester, UK) which are similar pieces of equipment that 
identify eutectic events. Both use DTA and the Lyotherm 1 measures electrical 
resistance while the Lyotherm 2 measures electrical impedance. A 5 ml liquid 
sample is placed in a vial and frozen to -70 oC using liquid nitrogen. For DTA the 
sample is then carefully heated in a heating block while the equipment measures 
the temperature within the sample and within a standard frozen solution (such as 
water) at the same time. Through plotting the differential thermal analysis one 
obtains a graph which shows an event at the Tg’ or Teu demonstrated by the 
divergence in the relative temperatures as shown in Figure 1.4. Regarding 
electrical properties, the Lyotherm 1 measured resistance of the sample as it is 
heated as shown in Figure 1.5. In Figure 1.5 the Tg’ is shown to be -33 oC as 
shown by the change in the graphs curvature. Lyotherm 2 measures electrical 
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impedance across the sample during warming as shown in Figure 1.6. The change 
in curvature occurs at the point of the Tg’. Due to the fact that the resistance of ice 
is in the mega-Ohm region, impedance gives a more reliable result. The research 
work behind both the Lyotherm 1 and 2 has been conducted by Louis Rey and is 
well documented (30). 
  
 
Figure 1.4 Differential thermal analysis chart (36) 
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Figure 1.5 Identification of Tg’ using electrical resistance measurement (36) 
 
Figure 1.6 Example of an impedance and differential thermal analysis 
warming profile for an aqueous solution of 5% (w/v) calcium chloride. 
Below -75 oC the amorphous CaCl2 (formed due to quench cooling in LN2) is 
becoming increasingly mobile as the temp increases, but crystallises between 
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-75 and -65 oC  which shows up as an exotherm in the DTA. The eutectic 
temperature of CaCl2 crystals is around -53 oC where you seen the 
impedance drop to minimal (full mobility) and the DTA shows the melting as 
an endotherm. (31) 	  
 
1.6.2 Freeze dry microscopy 
As the name suggests, this technique involves observing a sample as it 
freeze dries under a microscope. A drop (2–5 µL) of the sample is placed under a 
microscope slide and the slide is then placed on a heating/cooling shelf. Liquid 
nitrogen is then cycled through to freeze the sample in situ under controlled 
conditions. The microscope uses polarized light to allow the user to clearly 
identify when the material has frozen as shown in Figure 1.7.  
 
Figure 1.7 Sample of plasma and calcium chloride frozen under a freeze dry 
microscope. 
Once frozen, a vacuum is applied and the temperature of the sample is 
raised at a controlled rate. The controller can observe the sample lyophilizing on 
the microscope as shown in Figure 1.8. The procession of the dried front is clearly 
visible as the coloured region changes to grey due to the sublimation of the ice 
crystals which produce dazzling colours under plane polarised light. 
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Figure 1.8 Sample of plasma and calcium chloride lyophilizing under 
vacuum. The grey region is caused by the absence of water resulting from 
lyophilization 
The sample is continually heated under vacuum until the operator observes 
a situation similar to that seen in Figure 1.9. In this case, the sample temperature 
has exceeded the collapse temperature (Tc) of the sample and meltback occurs at 
the dry front. This allows the operator to determine the maximum product 
temperature acceptable during primary drying. 
 
Figure 1.9 Image showing the collapse temperature of the sample 
1.6.3 Differential scanning calorimetry 
This method involves the measurement of heat flow through a sample as it 
is heated. The science behind DSC and Modulated DSC has been well 
documented previously (32-36). As with the Lyotherm the operator is looking for 
an ‘event’ on a trace signifying either a glass transition temperature or a eutectic 
event. Figure 1.10 is an example of the trace one can expect from both amorphous 
and crystalline materials. The crystalline material gives a clear Teu at -21.18 oC 
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whereas amorphous materials result in a less clear ‘event’ labelled in Figure 1.10 
at -29.29 oC. 
 
 
Figure 1.10 Modulated DSC thermogram of three materials 
The primary use of all these methods is to determine the maximum 
allowable product temperature that is acceptable during primary drying before 
meltback occurs. In practice this defines the maximum shelf temperature for 
reasons that will be discussed in the following section. These methods can also be 
used to gather further detail about ones system such as how to anneal for larger 
crystals, or potentially to mimic the freeze drying process at low scale through the 
electron microscope (although research is necessary to understand how to scale up 
from 10 µl to 1 ml). DSC/MDSC is also used for product characterisation to 
understand the effect of storage temperatures. 
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1.7 Modelling the Lyophilization Cycle 
The lyophilization process is a coupled heat and mass transfer process. In 
order for water molecules to sublime they must have the energy to do so and there 
must be a driving force behind the movement. The rate limiting step behind the 
driving force in primary drying is different from that in secondary drying (37). 
Therefore the implication on process design modelling means that each stage must 
be treated differently. For example it is known the driving force behind primary 
drying is the difference in vapour pressure between the drying chamber and the 
vapour pressure of ice at the shelf temperature. Therefore, the chamber pressure 
can alter the rate of sublimation. However, in secondary drying Pikal (37) found 
that below 0.2 mmHg the drying rate was independent of the chamber pressure 
and depended more on temperature. This proves that there are two different 
mechanisms occurring during freeze drying (38) and each one dominates at a 
different stage. 
 
Modelling a coupled heat and mass transfer process with two different 
dominant mechanisms is complex. There have been several models proposed (17, 
39-43), but all of them rely on a generic system where assumptions are made 
about the product such as cake porosity, resistance to vapour flow etc. 
Furthermore, the models involve the use of complex mathematics which the 
average formulation scientist may not be acquainted with. The SMART freeze 
dryerTM uses manometric temperature measurement coupled with a steady state 
mathematical model (44) to give the user a product cycle. However, the modelling 
is conducted automatically by dedicated software and requires a capital 
investment for the dryer and associated software. 
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Early models were based on the Uniformly Retreating Ice Front Model 
(45) and were refined by later scientists but such models ignored vial geometry 
and temperature gradients within the vials rather assuming a steady state (46). In 
such models it is assumed that all energy transferred into the system is used to 
change the state of water from ice to vapour. This ensures the product temperature 
does not change. The models show that in the event that the sublimation cannot 
occur fast enough, the product temperature will increase beyond its Tg’ and 
meltback of the product will occur. Work carried out with pure ice demonstrated 
the unsteady nature of the ice front and lack of linearity in the shape of the ice 
front during sublimation (47,48). 
 
There exists a need for a system specific model that would allow the user 
to account for variations and demonstrate quality by design as shall be explained 
in more detail later. 
 
1.8 Process Analytical Technology (PAT) and freeze drying 
The Food and Drug Administration (FDA) promote the use of PAT in all 
areas of bioprocessing defined as a “system for designing, analyzing and 
controlling manufacturing through timely measurements of critical quality and 
performance attributes of raw and in – process materials and processes, with the 
goal of ensuring final product quality (49).” The ability to understand what is 
happening during a process helps validate the process and ensures consistency of 
product and process. Such monitoring technology must not interfere with the 
contents of the process stream in anyway, as such it must be non – invasive, non – 
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destructive and non – disruptive. Such technology allows the process engineer to 
demonstrate control over their process. The vast majority of freeze driers come 
with some PAT as standard and allow the user to monitor the shelf temperature, 
condenser temperature and pressure within the system. However PAT in relation 
to the product itself is an area that requires further work.  
 
The simplest form of PAT commonly used in lyophilization are 
thermocouples placed within the vial. These probes are either wired or wireless 
and measure the product temperature during freeze drying. Once drying is 
complete the product temperature is observed rising above the shelf temperature 
due to the fact that the energy the vial is receiving from the shelf via conduction, 
or the energy by radiation is not longer being used for sublimation. This causes 
the product temperature to rise as shown in Figure 1.11 where the product 
temperature can be seen rising above the shelf temperature from 20hrs. 
Temperature probes are relatively cheap, easy to use and most operators are 
familiar with the concept of thermometers and can understand the output. They 
allow timely measurements of critical parameters and give an indication of what is 
happening during the process. 
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Figure 1.11 Typical lyophilization profile (This example is from a flu antigen 
trial) 
Although the use of thermocouples does allow the user to see the endpoint 
out of hundreds of vials only 3-10 of them will have a thermocouple in them. 
Furthermore, the very presence of the thermocouple disrupts the ice crystal 
structure so the vials with thermocouples in them behave differently from those 
without. Finally, the vials with probes in are thrown away after freeze drying – the 
only vials about which the controller knows for certain what has happened are not 
even used! As such, although they are simple and cheap, they do not fulfil all the 
requirements of PAT. 
 
The microbalance technique has been documented by Pikal et al (50) 
where the proposed method involves the use of a small device, which periodically 
picked up and weighed a vial then put it back down on the shelf. Through the use 
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of this device Pikal et al determined the primary resistances to mass transfer 
during primary drying amongst other important results. As a PAT the mass 
balance is non – invasive and non – destructive and the vial can be used at the end 
of the process. However although the vial is only lifted off the shelf for a short 
time, the accumulated effect of multiple lifts from the shelf may have an impact 
on the heat transfer to the product. Neighbouring effects from nearby vials are non 
existent as the vial to be lifted is isolated from any neighbours. Also this only 
measures one vial and there is documented evidence that shows vial – to – vial 
variability occurs. Therefore until someone develops a method of weighing all the 
vials directly in the dryer, this is not an optimum PAT. 
 
An early novel form of PAT in lyophilization was the windmill device 
(51). This involved the use of an aluminium impeller with a needlepoint axle and 
sapphire bearings to reduce friction as much as possible. The pressure difference 
caused by the flow of water vapour would result in a spinning windmill. When the 
operator saw the windmill stop spinning he would know the end of the primary 
drying phase had been reached. This meant the operator needed to regularly check 
the windmill visually. Experiments showed that the windmills continued to spin 
after the product temperature reached the shelf temperature suggesting that they 
were still spinning after the primary drying phase had ended. This could have 
been due to the frictionless bearings. Either way it was not considered a robust 
enough method to pass regulatory approval. 
 
It has been shown that it is possible to monitor the rate of sublimation 
within a vial using Fourier Transform Infrared Spectroscopy. This method 
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involves the use of a non – invasive probe which can monitor the quantity of ice 
remaining in the vial. However, due to the size and type of probe there are issues 
involving sterility and ease of use. While these issues are not insurmountable the 
end result would still be a technology that only measures one vial in 500 which 
would not give the user sufficient information to demonstrate control over the 
system.  
 
The pressure rise test has been shown to allow the user to determine the 
end point for lyophilization (5). In this method, the valve between the condenser 
and the drying chamber is closed. The vacuum pump is behind the condenser so 
the valve shuts off the connection between the pump and the drying chamber. The 
pressure within the chamber rises due partially to unavoidable leaks but primarily 
due to the vapour subliming off the vials. This continues until the pressure in the 
chamber reaches the vapour pressure of the ice front in the vial. By correlating 
this with thermodynamic data tables one can work out the temperature of the ice 
front. Furthermore, should the pressure not change at a quicker rate than the leak 
rate of the chamber one can infer that the drying has finished.  A major advantage 
of this is the lack of requirement for any additional equipment assuming one has a 
valve between the chamber and condenser. Another method includes manometric 
measurement comparisons between a Pirani and Capacitance manometer. The 
Pirani Gauge is known to be slightly inaccurate due to the presence of water 
vapour whereas this does not affect the capacitance manometer. Therefore when 
both are present in line with the freeze dryer system, if they both read the same 
measurement one can infer there is no water vapour and the drying process is 
over. Through combining these two methods, the Smart Freeze Dryer was 
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developed (52) which optimizes the cycle based on the data received through a 
combination of the two above methods. While this is undoubtedly a great 
achievement in the lyophilization field, it is a batch – based system in the sense 
that it only gives information about the overall batch rather than individual vials 
which still leaves room for further development. 
 
Another batch method of PAT worth mentioning involves the insertion of 
an infra – red spectrometer or a mass spectrometer in – line between the chamber 
and condenser. By analyzing the process stream between the two one can work 
out when the endpoint has been reached.  However this involves retro – fitting an 
existing system and validating it in terms of both sterility and leak rates. 
Furthermore it is again only a batch analytical technology. 
 
This discussion not only highlights the requirement for PAT in 
lyophilization but also highlights the difficulties involved with lyophilization. The 
issue is that unlike most if not all other bioprocesses where there is one reactor, 
one chromatography column, one membrane, one system, in lyophilization each 
vial is an individual system/reactor on its own making lyophilization effectively 
hundreds or thousands of small unit operations each requiring their own PAT. 
1.9 Quality by Design (QbD)  
Whereas in the past, process validation protocols demanded process 
parameters were kept constant to ensure consistent product development, 
regulatory bodies came to accept that it is impossible to ensure no variation occurs 
in the lifetime of a bioprocess. Suppliers of raw materials can change, accidents 
can happen and further scientific knowledge can impact on design. The emphasis 
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shifted onto ensuring a consistent product which does not automatically imply a 
consistent process. The FDA coined the term design space defined as the 
“multidimensional combination and interaction of input variables and process 
parameters that have been demonstrated to provide assurance of quality (53).” 
This meant that the process designer must have a demonstrated knowledge of the 
sensitivity of the process to variations in the process parameters. Having identified 
the region of operability within the design space, any variation within the region is 
not considered a change and would not then require the initiation of a regulatory 
post approval change. 
 
This means that when designing lyophilization processes one can account 
for variabilities in the process so long as previously documented evidence exists 
to demonstrate safety and consistency in product quality. The use of designed 
experiments to map the design space can be an invaluable tool as explained in 
section 1.10. 
 
1.10 Ultra scale down and design of experiment 
The use of factorial design of experiment (DoE) software is becoming 
increasingly popular in industry for screening and optimising processes, 
particularly in fermentation.  Such methods have been shown to be advantageous 
in rapid screening experiments compared to traditional systematic one-factor-at-a-
time (OFAT) approaches (54).  Ultra scale-down (USD) studies have been used 
for many industrial processes such as fermentation (55), centrifugation (56), 
microfiltration (57), chromatography (58), and protein refolding (59), and also for 
studying fundamentals such as mixing (60,61), and the thermostability of proteins 
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in response to environmental conditions and additives (62) as well as formulation 
(63-65).  The large datasets that can be rapidly accumulated with these methods 
lend themselves well to DoE methodologies.  For example, ultra scale-down of 
fermentation has also been recently carried out in conjunction with statistical 
experimental design (54) to achieve optimisation of soluble protein expression in 
E. coli.   
 
Factorially designed experiments allow the user to cover a far wider area 
of the design space that traditional one factor at a time (OFAT) approaches. For 
example Figure 1.12 demonstrates a traditional approach to formulation design. 
An optimum is found for trehalose while keeping other excipients constant. It is 
then held at the optimum and the next excipient under investigation is varied and 
so on. As Figure 1.12 shows, vast areas of the design space are left unchartered. 
Furthermore, if there is an interaction, ie if the whole is greater than the sum of 
the parts, one will never identify such an interaction by varying one factor at a 
time. However by varying all the factors at the same time as seen in Figure 1.13 
one gains a much better understanding of the design space thus increasing the 
efficiency of process development. 
 
DoE also lends itself well to validation. It allows the user to understand the 
entire design space and conduct sensitivity analysis to understand the impact of 
variations. However DoE can result in multiple experiments. This is where ultra 
scale down is useful. As has been mentioned before elsewhere, during early stage 
development the quantity of material is often limited. The use of ultra scale down 
methods allows more data to be gathered from less material. By combining this 
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with DoE one can really streamline process development. Furthermore, ultra 
scale-down methods involve the use of microtitre plates, a standard format for 
which robotic systems already exist. In other words, it lends itself well to 
automation which is a major advantage. 
 
Figure 1.12 OFAT approach to formulation development 
 
Figure 1.13 DoE approach to formulation development 
1.11 Aims of this thesis 
Currently the methodology used to identify optimum formulations and 
drying cycles is highly empirical. Formulations are often chosen on the basis of 
experience (it has worked with something else) sketchy scientific knowledge (this 
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formulation works in liquid form) or even at random. The current literature does 
not contain any systematic approaches to formulation development. Current 
research methods aim to determine relationships between classes of 
biopharmaceuticals and excipients. The aim of these methods is to utilize such 
relationships to predict ideal formulations. However with the increasing 
complexity of antibodies manufactured for therapeutics, the ability to classify 
antibodies is limited. Genetic modification of antibodies make classification even 
harder and with the introduction of peptides an intelligent targeted approach to 
formulation development would be ideal. It is unlikely that such an approach will 
exist within the near future.  
 
Drying cycles are frequently over-engineered resulting in unnecessary 
lengthy cycles. Although the steady state model allows prediction of a drying 
cycle and associated parameters, it involves estimating critical parameters such as 
resistance to mass flow. More importantly, the intelligent freeze dryer which 
utilizes steady state models and the pressure rise test to determine cycle 
parameters, does not show where the edges of failure are. Indeed, the 
recommended cycle could even be on the edge of failure. In terms of QbD, this is 
not ideal. 
 
This thesis aims to develop a systematic step - by - step approach which 
the engineer can use to develop and optimise a formulation for lyophilization. 
Such a platform technology would allow the user to optimise formulation 
development easily and gain sufficient understanding to allow process validation 
as well as an optimum formulation. Furthermore, the use of DoE will be used to 
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develop an empirical specific process model to allow the user to optimise the 
lyophilization cycle. The resultant model will provide a detailed map of the design 
space showing the edges of failure. Such a method allows for a quality by design 
approach to cycle development which, until further steps are made in PAT, are 
vital in lyophilization development. 
1.12 Objectives of this thesis 
• To identify scale up factors between microplates and vials 
o Freeze dry water in different scale containers 
o Compare results to identify scaling parameters 
• Develop a high throughput platform technology for formulation 
development 
o Working in microwells, utilize DoE to screen for and optimize an 
ideal formulation 
o Validate the resultant formulation in full scale containers 
• Validate that the formulation development platform developed works for 
more complex products 
• Utilize DoE to develop a generic model for cycle development 
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Chapter 2. Investigation into the Key Parameters That Effect 
Sublimation Rate at Different Scales 
2.1 Introduction  
Ultra scale down is a technique whereby industrial scale bioprocesses are 
mimicked on such a scale that microlitres of material are used.  Much work has 
been carried out to date using such methods to predict process conditions on scale 
up from microscale to pilot scale to industrial scale.  Work done to date has 
included studying the impact of shear on microbial cells (66), optimisation of cell 
recovery processes such as filtration and centrifugation (56-57, 67), expanded bed 
adsorption chromatography (68) and protein stability studies (62).  By minimizing 
the volume of material used such methods increase the efficiency of research and 
development investigations in terms of data gained per gram of material used.  To 
date, little work has been carried out using ultra scale down to optimise freeze 
drying.  Some work has been carried out in PCR well plates (69) however the 
shape of PCR wells does not lend itself well to effective heat transfer during 
lyophilization, or correctly mimic lyophilization vial geometry. Currently work 
carried out in the lab and pilot scales to optimise freeze-dried formulations and 
processes is performed in the same sized vial as those used in an industrial scale 
lyophilization run, from which a larger process is achieved by scaling out rather 
than scaling up.  This process of scaling out is not without its own factors that are 
scale dependant.  Each vial is essentially a semi-independent mini-lyophilization 
process and as such, one can expect variations to occur between vials.  For 
example, the heat transfer into the sample is known to vary depending on the 
positioning of the vial on the freeze-dryer shelf.  The heat transferred by radiation 
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is known to create edge effects whereby the outer vials are heated more quickly 
resulting in faster rates of sublimation (14, 16, 68). Furthermore,  the initial stage 
of lyophilization is a non-uniform and partially random event where different 
vials, especially those containing different formulations, can freeze at different 
times and temperatures resulting in different sized ice crystals (70).  Having 
multiple reactor vessels make Process Analytical Technology (PAT) for freeze-
drying extremely challenging (71), although solutions such as the pressure rise 
test which measures the vapour pressure of water present in the chamber at any 
one given moment in the sublimation process (72) have shown themselves worthy 
of use in commercial processes.  
 
The determination of viable formulations and processes for freeze drying 
is still done largely empirically.  New biopharmaceutical products are typically 
compared to similar existing lyophilized proteins for which a good formulation is 
already known, and the new formulation obtained by an iterative adaptation of the 
previous one.  While a great deal of fundamental work has been done to increase 
our understanding of the mechanism by which different excipients act as cryo- 
and lyo-protectants (31, 73-76), the variety and novelty of new protein based 
products have resulted in a critical need for a more systematic screening process 
for the identification of viable formulations that preserve the product during 
lyophilization.  Such a process would have to use minimal quantities of material 
as the research would be carried out on 99.99% pure product during early process 
development when any product available would be costly and available in small 
quantities, and also needed for the clinical trials.  Conducting such research at the 
ultra scaledown level in microtitre plates presents a clear advantage provided a 
 52 
suitable mimic for larger vials can be found.  As well as the advantage of using 
minimal material, microtitre plates have the added advantage that they lend 
themselves well to automation as robotic equipment already exists that uses the 
microtitre format. 
 
Before the data from research carried out in microtitre plates can be relied 
upon, the factors that are affected through lyophilization at such a small scale 
must be identified and characterized to demonstrate that they behave similarly 
upon scale – up to the vial.  The factors that influence the rate of freeze drying 
within vials have been identified and well characterized in terms of heat transfer 
into the vial, sublimation at the ice front, mass transfer out of the vial, and 
resistance to vapour flow (14).  Heat transfer from the shelf into the vial is partly 
influenced by the heat transfer coefficient of the material the vial is made from.  
As vials are made from glass and the microtitre plates used made from plastic and 
as each vessel had difference wall thicknesses, this had to be taken into account. 
Resistance to vapour flow is primarily dependant on the porous cake formed by 
the freeze dried product (14). During this investigation the process was simplified 
as the product investigated was pure water. This removed the resistance to vapour 
flow factor and the secondary drying stage completely as no residual cake would 
be left after the water had sublimed. 
 
In any process it is important to characterizing the reactor vessel and 
lyophilization is no different (14, 77). Furthermore when scaling a process down 
one has to characterize the scale down system and understand how it relates to the 
full scale reactor vessel. Otherwise data gathered at the scale down level cannot be 
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applied to full scale and does not achieve anything. This investigation looks at the 
key factors that affect the sublimation rate of ice under vacuum in different 
vessels. The results give an insight into the parameters that must be controlled 
during scaling the process up or down during primary drying. Using the results 
from this investigation, valid predictions will be made based on comparing scale-
down experiments to the larger scale systems. 
 
2.2 Materials and Methods 
Three vessel types were used during this investigation: 5 ml glass vials, 3 
ml glass ampoules and wells within 96-well flat bottomed polystyrene Sarstedt 
microtitre plates.  The physical dimensions of the vessels and the fill volumes 
used are shown in Table 2.1.  All three vessels had the same cylindrical geometry 
although the diameter to height ratios differed.  The fill depth was kept constant 
within all vessels to ensure that heat transfer from the shelf to the material was the 
same across all vessel types.   
 
 
Table 2.1 Physical dimensions and fill volumes for vials, ampoules and wells 
Five vessels of each type were filled with the corresponding volume of 
Reverse Osmosis (RO) water.  The vials and ampoules were then weighed and all 
three sets of vessels were placed on the shelf of an Edwards Modulyo Freeze drier 
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(Edwards BOC, Crawley UK) frozen in situ to -20 oC and held for 1.5 hours.  A 
vacuum of approximately 85-100 µbar was then applied for 20, 40, 60, 80 or 100 
minutes to all vessels.  The vacuum was released, the remaining ice was then 
allowed to melt at room temperature and the remaining volume of liquid was 
determined either by weighing again in the case of the vials and ampoules or by 
volumetric determination using a gas tight 250µL gastight Hamilton Syringe. 
 
2.3 Results and Discussion 
The results of the sublimation experiments for all vessel types can be seen 
in Table 2.2, however they can be compared more clearly in Figure 2.1.  
 
Table 2.2 Results of sublimation experiments 
 
Figure 2.1 Average sublimation of ice in 5 microwells, 5 ampoules and 5 vials 
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At all scales the mass of water lost by sublimation remains proportional to 
the time for which sublimation was allow to proceed.  The vials showed the 
greatest rate of sublimation, followed by the ampoules and then the 96-well 
microplates.  This trend was expected as the vials had the widest base diameter 
thereby providing the greatest surface area in contact with the freeze-drier shelf.  
This surface area has already been identified as a key factor in influencing the rate 
of sublimation (14, 70) and the relationship between surface area and sublimation 
rate is given by Equation 2.1.  The gradient of the lines in give the water 
sublimation rates for each vessel in mg/min which Equation 2.1 shows is affected 
by the surface area (A).  However the other parameters in Equation 2.1, i.e. 
vapour pressure, chamber pressure and the resistance to vapour flow, were the 
same for all vessels used.  
 
Figure 2.2 shows a plot of the sublimation rates calculated using the 
results from Figure 2.1 against the surface areas of each vessel.  As expected from 
Equation 2.1 there is a linear relationship between the surface area and the 
sublimation rate where the sublimation rate increased with surface area. 
 
Equation 2.1 Sublimation rate during primary drying where dm/dt is the rate 
of mass transfer, A is the cross sectional area of the vessel, P0 is the 
equilibrium vapour pressure of ice at the temperature of the frozen material, 
Pc is the chamber pressure and R is the resistance to vapour flow by dried 
product 
 56 
 
Figure 2.2 Linear relationship between sublimation rate during freeze-drying 
and the surface area of the vessel in contact with the freeze-drier shelf 
That the sublimation rate increased with an increase in the surface area is 
not surprising.  A higher surface area means that there are more ice molecules at 
the air/solid interface that are able to sublime at any one moment.  It would 
therefore be expected that the specific rate of sublimation, i.e. the rate of 
sublimation per unit area, should remain constant regardless of the vessel.  
However this is not the case as shown in Table 2.3, and also because although the 
relationship in Figure 2.2 is linear, the plot does not pass through zero.  The 
microwells have a far higher specific rate of sublimation than for ampoules, which 
in turn is slightly greater than the vials which have the greater surface area. 
 
 
Table 2.3 Sublimation rate per unit area for three vessels 
One could argue that the differences in specific sublimation rate are due to 
variations in the thermal transfer coefficients of the materials that the vessels are 
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made from.  However, the thermal transfer coefficient of glass is actually greater 
than the polystyrene of the microplates, and the thickness of all three vessels are 
comparable. Furthermore, the ampoules and vials are both made from the same 
type of glass, and so one would expect them to have similar specific sublimation 
rates.  Visual observation of the recession of the ice front during sublimation 
reveals that, contrary to popular models used to predict sublimation rates (14, 50, 
52, 77-78), the ice front does not recede uniformly but shrinks away from the 
walls of the vessel as well as from the surface of the ice.  This implies that 
sublimation at the edges of the air/solid surface of the sample is more rapid than at 
the centre of that surface. This could be due to a combination of two factors. 
Firstly, the walls of the vessel are made from hydrophobic materials. It is 
reasonable to assume that the bonds between the ice molecule and the wall at the 
ice-wall interface are weaker than the ice-ice interactions in the centre of the 
vessel. Therefore less energy is required to break them and allow the ice molecule 
to sublime. This leads to the second factor which is that ice is an excellent 
insulator, which suggests that there must be a thermal radial gradient across the 
ice making the ice in the centre colder and less likely to sublime. 
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Figure 2.3 Relationship between contact area to volume ratio and specific 
sublimation rate 
Looking at the ice – wall interface factor more closely the influence can be 
observed by relating the surface area of this interface with the total volume of the 
fluid. All the vessels were placed under the same conditions and lyophilized at the 
same time and all the vessels had the same fill depth of ice. As expected the vials 
which had the largest diameters sublimed the fastest. However, if we look at the 
sublimation rate per unit area one would expect them all scales to be the same, 
whereas Table 2.3 shows microwells sublime faster. By combining this fact with 
the ice – wall interface theory one can understand that the microwells are smaller 
units and as such have a larger ice – wall interface surface area than any other 
vessel. Figure 2.3 demonstrates this relationship well as it is a plot of the ratio of 
ice – wall interface to the volume of fluid within against the specific sublimation 
rate.  Essentially the ice – wall interface to volume ratio is a measure of surface 
area. Surface area is known to be an important factor in any reaction – ground 
powder reacts quicker than large particles. So too, microwells “react faster” or 
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sublime quicker than vials. This is important because it implies that the presence 
of a probe or anything that increases the ice – wall interface area will speed up the 
sublimation. 
 
Furthermore, as the ice immediately next to the wall of the vessel 
sublimes, the remaining ice comes into direct contact with the air.  Although one 
may picture the water vapour rising from a flat ice front a more realistic picture is 
a conical ice front where the vapour flow travels in multiple directions as shown 
in Figure 2.4. 
  
Figure 2.4 Direction of vapour flow with a flat ice front and a conical ice 
front 
 
2.4 Conclusion 
This investigation aimed to understand the parameters that need to be 
understood when using microwells as a scale down mimic of a vial based system 
and assess the validity of any data gained. Through this investigation it has 
become clear that it is possible to freeze dry materials in microwells and that the 
results could potentially be used to predict large scale operations. Although the 
rate of sublimation is different in microwells from vials, this can be explained and 
measured by determining the size of the ice-wall interface in relation to the total 
volume of ice. Once that is determined the relationship between that and the 
specific sublimation rate is a linear one and predictions can therefore be made 
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from one vessel to the other. However, this has been difficult to prove for a 
product containing solids due to the limitations of Karl-Fischer titration in relation 
to microtitre plate freeze drying. The titration required the mass of solid present in 
the well which is in the order of micrograms. However the plate weighs 
approximately 10 grams and there was no balance available that could measure 10 
grams to the precision of a microgram.   
 
The sublimation of ice requires energy which is supplied primarily through 
conduction (14), but convection and radiation are important factors too. 
Conduction occurs from the shelf through the bottom of the vessel into the ice. 
According to the second law of thermodynamics, wherever there is a temperature 
difference, thermal energy will spontaneously flow from the hotter body to the 
cooler body. Therefore, if the vessel itself is at a higher temperature than the ice 
within, thermal energy must transfer from the vessel wall to the ice. A higher 
temperature of ice means a higher vapour pressure which in turn means the 
pressure difference between the vapour pressure of that ice particle and the 
chamber pressure is higher thereby promoting a faster sublimation rate as shown 
in Equation 2.1. This effect results in the characteristic conical shape observed 
within the vessels. It would be interesting to find out if there is a temperature 
gradient within a vial from the bottom to the top during freeze drying. This would 
probably necessitate a freeze dryer with an infra red transparent door. 
  
In conclusion one can say that when scaling up from a microwell to a vial, 
or even from an ampoule to a vial, the surface area in contact with the walls of the 
vessel must be taken into account. Scale up can be considered in terms of constant 
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volume or constant fill depth. There is much scope for further work, particularly 
with a real product that forms a porous plug on top of the receding ice front. Such 
a plug would affect the sublimation rate. With water, the sublimation rate was 
linear but one would expect the sublimation rate of a product to steadily decrease 
as the dried layer increases. This is due to the resistance to mass flow caused by 
the dried layer. The thickness of the layer is increasing with time, but the rate at 
which it increases is dependent on the sublimation rate. To date, attempts to 
measure the moisture content of freeze-dried materials in microwells using Karl 
Fischer titration have been unsuccessful (data not shown). The need to weigh the 
quantity of material within the well accurately has proved difficult. There now 
exists a technique of moisture analysis called thermo-gravimetric analysis. In this 
method, a pan approximately 5 mm in diameter is weighed and then filled with 
the freeze dried material under nitrogen in a dry box. It is then sealed and weighed 
again to give the mass of material under test. The pan is then pierced and heated 
and the gasses released are run through a mass spectrometer. The mass 
spectrometer allows the user to identify the moisture content present in the sample 
and differentiate it from any water released due to thermal decomposition. Due to 
the quantities used, such a method potentially lends itself well to ultra scale-down. 
 
 It can further be concluded that the presence of foreign objects such as 
thermocouples in vials during freeze drying conduct heat into the ice and will 
therefore interfere with the lyophilization within that vial. As such, thermocouple 
analysis is not representative of all the vials undergoing lyophilization. 
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 Although microwells would never be a perfect mimic for vials due to the 
geometric constraints such as the thickness of the vessel wall and indeed the 
material which the wall is made out of, through the use of thermo gravimetric 
analysis one could screen a process design and identify maximum shelf 
temperatures and minimum chamber pressures outside which the run could fail 
through cake collapse or blowout. 
 
 In terms of the aims of this thesis, aside from the thermo gravimetric 
analysis which has only recently become available, it was decided not to use ultra 
scale-down to predict drying cycles, due to the inability to determine how dry a 
sample in a microwell is. However, in terms of formulation screening and 
optimisation, this investigation showed that it is possible to freeze dry samples 
within microwells. Therefore the next step was to combine ultra scale-down with 
factorial design to identify optimum formulations for freeze-drying proteins. 
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Chapter 3. Rapid Optimisation of Protein Freeze-Drying 
Formulations Using Ultra Scale-Down and Factorial Design of 
Experiment in Microplates1 
 
3.1 Introduction 
Having established that it is possible to freeze dry material in microtitre 
plates this investigation looks at the use of ultra scale down to identify optimum 
formulations for freeze drying. Due to the ever increasing complexity and costs of 
manufacture of biopharmaceuticals, there exists a need for the development of a 
rapid screening technique that allows the user to find an ideal formulation for the 
preservation of proteins during freeze-drying, while minimising the quantity of 
precious materials used.  The formulation and process parameters for freeze-
drying must maintain the protein stability both during the process and in 
subsequent storage (31, 72).  Freeze-drying must also result in a product with an 
elegant cake structure, no signs of meltback or collapse, and a low residual 
moisture content (31).  Although much is currently understood about the process 
and the mechanisms by which excipients such as PEG and sugars protect proteins 
during freezing and drying (79, 80), an empirical approach is generally used for 
new protein products (72).  A basic formulation design is typically taken as a 
starting point, where buffers, bulking agents and stabilizers are chosen using as 
much scientific knowledge as possible about the protein product.  This process 
                                                 
1 Grant Y, Matejschuk P, Dalby P. Rapid optimization of protein freeze – drying 
formulations using ultra scale – down and factorial design of experiment in 
microplates Biotechnol. Bioeng. 104(5), 957-964 (2009) 
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can be time consuming, material intensive and costly due to the hit and miss 
approach taken and the number of repeats required to validate the results. 
 
As mentioned earlier in the introduction, the use of factorial design of 
experiment (DoE) software is becoming increasingly popular in industry for 
screening and optimising processes. Here we combine the use of statistical 
experimental design with ultra scale-down methods in a microplate format to 
optimise the formulation for stability to freeze-drying, using small quantities of 
protein. 
  
The enzyme lactate dehydrogenase (74) was chosen as a suitable model 
protein to investigate the USD methodologies as it was known to be inactivated 
during lyophilization (79).  Furthermore LDH has been used in the past as a 
model protein in lyophilisation experiments (73, 74) and has been well 
characterised in terms of protein structure (81) and protein subunit dissociation 
(82).  Lactate dehydrogenase catalyses the interconversion of pyruvate and lactic 
acid using NADH as a cofactor, thus also providing a simple assay amenable to 
use in microplates similar to the procedure described by Krieg et al (83). 
3.2 Materials and Methods 
PEG (MW 2000), Dextran, Glycine, Sodium Pyruvate, Sodium Phosphate 
(monobasic and dibasic), trehalose, and Lactate Dehydrogenase (from 
Lactobacillus leichmanii) were all purchased from Sigma-Aldrich Chemical Co 
(Poole, UK). NADH was purchased from Calbiochem (Nottingham, UK), lactose 
and arginine from VWR (Leicestershire, UK), sucrose from FSA (Loughborough, 
UK). LDH (282 U/mg) was purchased as a lyophilized powder and was 
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resuspended for baseline assaying in 100mM phosphate buffer at pH 7.0 or for 
lyophilization in 50mM phosphate buffer at pH 7.0 and diluted to the desired 
concentration.  The 96 well microplates were purchased from Greiner (Greiner, 
Stonehouse UK) and the bottom lips trimmed off such that the bottom of the wells 
rested directly on the freeze drier shelves. 
 
3.2.1 Determination of edge effects for sublimation from a microplate 
Into each of the 96 wells of 3 microplates was pipetted 200 µL of water 
and then frozen at -20oC.  The plates were then partially freeze-dried under 
vacuum at -20oC for 90 mins.  The remaining ice was then thawed and measured 
volumetrically for each well using a 200 µL gas-tight Hamilton syringe. The 
results from each well on each plate were averaged and plotted in Figure 3.1. 
 
Figure 3.1 Distribution of the remaining volumes (µL) of water present in 
each well of a microplate, after partial freeze-drying of 200 µL at  20 oC for 
90 mins. All points represent an average that had a variability of 5%. 
3.2.2 Lactate dehydrogenase activity measurement in microplates 
LDH activity retention was measured as a percentage of the original 
activity.  Initial activity was determined for the conversion of pyruvate to lactic 
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acid.  The total powder in a vial of LDH containing 52.4% protein in 3.4-3.5mg 
solid at 282 U/mg was dissolved in 5 ml 100 mM phosphate buffer, pH 7.0 for a 
stock concentration of 100 U/ml.  A solution of 0.5 U/ml LDH was made from 
100 µL stock solution and 19.9 ml 100 mM phosphate buffer, pH 7.0.  To each 
well of a flat bottomed 96-well Greiner microplate (Greiner, Stonehouse UK) was 
added 20 µL of the 0.5 U/ml LDH and 180 µL of each excipient combination with 
NADH in 100 mM phosphate buffer, pH 7.0, giving final concentrations of 
0.05 U/ml LDH and 0.5 mg/ml NADH.  Excipient concentrations were varied as 
specified in Table 3.1 and Table 3.2. Six replicates per formulation were 
incubated for 20 mins to allow equilibration of the NADH into the LDH.  To 
initiate reactions, 100 µL of 10 mg/ml sodium pyruvate in 100 mM phosphate 
buffer, pH 7.0 was added and the absorbance at 340 nm measured in a Versamax 
Plate Reader (Molecular Devices, Wokingham UK) every 30 seconds for 20 
minutes. The absorbance was measured for 20 mins and plotted on a chart. The 
decrease in absorbance over the first four minutes was always linear. The gradient 
of the graph over the first four minutes was used to identify the initial activity of 
the LDH. 
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Table 3.1 Percentages by weight of excipients present in initial screening 
design formulations for freeze-drying of LDH in microplates 
 
Table 3.2 Percentages by weight of excipients present in the DoE optimisation 
formulations for freeze-drying of LDH in microplates 
3.2.3 LDH freeze-drying and activity measurement in microplates 
LDH (0.05 U/ml) was prepared as above in 200 µL aliquots of 50 mM 
phosphate buffer pH 7.0, containing the relevant excipient combinations, with 6 
wells per formulation.  The position of each formulation in the microplate was 
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randomized by the Design Expert v7 software (Stat-Ease, Minneapolis, USA).  
Due to potential edge effects all outside edge wells were filled only with buffer.  
Microplates were placed in a Virtis Genesis 25EL freeze dryer (Biopharma 
Process Systems, Winchester, UK) and the samples freeze dried under the 
conditions shown in Table 3.3. The cake was then re-suspended in 200 µL 50 mM 
phosphate buffer containing 0.5 mg/ml NADH bringing the total concentration of 
phosphate buffer to 100 mM. Following a 20 minute incubation period, 100 µL of 
10 mg/ml sodium pyruvate in 100 mM phosphate buffer was added and the 
activity measured as above.  
 
 
Table 3.3 Lyophilization cycle used for ultra scale-down experiments in 
microplates 
A fractional factorial design was initially used to identify the effects of 
seven excipients on the preservation of LDH activity during freeze drying. The 
seven excipients chosen were selected based on their suitability as FDA approved 
additives, and on their use in previous protein formulation studies.  Concentration 
ranges were set to indicate likely lower and upper concentrations derived from 
such studies (102).  The concentration ranges used for these excipients are shown 
in Table 3.4.  The design matrix for the fractional factorial screen is shown in 
Table 3.5 and is presented in the randomised order used.  Each condition was 
measured once, except the condition with all excipients at their midpoint values 
which was performed in triplicate.  This design matrix provides eight conditions 
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for both the high and low concentrations of each excipient. The measured effect of 
a factor is therefore a measure of the average effect caused when that factor 
switches from its low value to high value. As such, in this experiment the 
measured effects for each factor are the results of eight repeat experiments. 
 
Table 3.4 Excipients and concentration ranges investigated in the factorial 
screening and DoE optimization experiments 
 
Table 3.5 Design matrix for the factorial screening investigation of excipient 
effects on retention of LDH activity after freeze-drying in microplates.  A 
value of -1 represents the lowest concentration setting for each factor, 1 the 
highest and 0 the midpoint 
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The experiments for optimisation of PEG and lactose excipient 
combinations in microplate freeze-drying were designed in Design Expert v7 
using random surface modelling and a central composite face design, based on the 
results from the initial fractional factorial investigation.  All factors are varied at 
three levels, high middle and low, to accurately develop a model including any 
curvature.  The design matrix for the optimisation is shown in Table 3.6.   
 
Table 3.6 Design matrix for the DoE optimisation investigation of excipient 
effects on retention of LDH activity after freeze-drying in microplates. A 
value of -1 represents the lowest concentration setting for each factor, 1 the 
highest and 0 the midpoint 
3.2.4 Verification of optimal freeze-drying formulation in vials  
To validate that the formulation selected through the microplate model 
was appropriate for products lyophilised in vials a scale-up study was performed. 
The formulations shown in Table 3.7 were made to a fill volume of 1ml in 22mm 
vials (Adelphi Tubes, Haywards Heath, UK) and then lyophilized using the cycle 
shown in Table VIII in a Virtis Genesis 25EL freeze dryer (Biopharma Process 
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Systems, Winchester,UK). The material was then re-suspended and pipetted into 
microplates to be assayed for activity as described above. 
 
Table 3.7 Formulations used for scale up experiments for freeze-drying in 
22mm vials. Excipient concentrations are shown as percentage by weight in 
50 mM phosphate buffer, pH 7.0. Prediction and actual activity retentions for 
the formulations are given as a percentage compared to the initial activity 
3.3 Results and Discussion 
3.3.1 Edge effects present on a microplate 
The volume of water remaining in each well of a 96-well plate, after 
partial lyophilization for 90 minutes, as measured using a Hamilton syringe is 
shown in Figure 3.1. The average standard deviation from plate to plate, of the 
volume remaining within each well was 5.9 µL. Wells on the edge are shown to 
have a smaller volume of water remaining inside them after sublimation than the 
wells in the centre. This would indicate that sublimation was occurring more 
rapidly in the outer wells and is likely due to thermal transfer via radiation from 
the sides of the dryer.  The complete lyophilization cycle used for the LDH 
formulations (Table 3.3) was designed to remove all of the ice by sublimation 
over a period of 600 minutes, leaving a similar final residual moisture content in 
all wells.  However to minimise any potential problems that could occur due to 
different sublimation rates during DoE experiments, it was decided that the outer 
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wells should be filled with buffer and only the inner wells used for LDH 
lyophilization. 
3.3.2 Fractional factorial design of the effects of excipients on freeze drying  
Seven excipients were initially chosen for investigation into their ability to 
preserve the protein during the freeze drying process and the chosen ranges are 
described in Table 3.4.  These widely used excipients are all generally regarded as 
safe for use with biopharmaceuticals.  The ranges for each excipient were chosen 
based on typical concentrations used in industrial processes (31, 72).  A full 
factorial design for 7 factors would typically mean 128 individual experiments 
which would identify all interactions between multiple factors.  For the screening 
investigation a lower resolution was chosen to lower the overall number of 
experiments necessary while providing sufficient information to identify the main 
effects and potential 2-factor interactions for further investigation and 
optimisation.  The design matrix for the fractional factorial screen is shown in 
Table 3.5 using coded values where -1 represents the low value for the excipient 
concentration (0% w/w), 1 represents the high value for excipient concentration 
(as shown in Table 3.4) and 0 represents the mid-point value.  As shown in Table 
3.5 runs 13, 18 and 19 contain all excipients set to their respective mid-point 
values.  This formulation represents the centrepoint of the design space and was 
repeated three times to allow a measure of accuracy to be determined.   
  
The purpose of these experiments was to rapidly identify which 
compounds had a positive effect on the maintenance of the stability of lactose 
dehydrogenase during lyophilization.  Data collected from the plate reader assay 
was plotted on a half normal plot as shown in Figure 3.2.  Points on a half normal 
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plot that deviate significantly from the straight line represent factors that have a 
significant effect on the retention of activity.  In this experiment factor B (PEG 
2000) was seen to have a strong effect on activity retention.  The point labelled 
BC also shows a strong effect from a lactose–PEG interaction.  It is important to 
note that as this was a fractional factorial where two-factor interactions were 
aliased, and so BC could also be AE (arginine – sucrose) or DF (trehalose – 
dextran).  However as PEG was already shown to have an effect on activity 
retention and none of the other possible factors had a significant effect, it was 
reasonable to assume that the interaction involved PEG.  The other factor in the 
interaction was lactose so this was included in the subsequent model and 
optimisation to maintain the hierarchy. While we do not study time-dependent 
degradations during storage, lactose is known as a reducing sugar and can lead to 
take part in Maillard reactions which could result in degradation of the product 
over time in storage. However several biopharmaceutical products currently use it 
in their formulations to maintain activity (84).  Analysis of variance (ANOVA) of 
the model gave a p-value of 0.0002 showing that the model is statistically 
significant.  This means that the model was sufficiently accurate to determine key 
factors with potential for optimisation.  The model plot in Figure 3.3 shows the 
interaction between lactose and PEG.  At lower concentrations of PEG, increasing 
the concentration of lactose results in an increase in activity retention of 24% 
whereas at higher concentrations of PEG the 95% confidence intervals overlap 
suggesting that statistically there should be no difference.  Also, the intersection 
of the two lines is not on the centre points at 0.25% PEG, suggesting that a linear 
model is inaccurate and that there should be some degree of curvature in the 
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model. Therefore determination of the optimum concentrations of excipients 
required a higher level factorial experiment.  
 
Figure 3.2 Half normal probability plot for the effects of excipient 
combinations upon retention of LDH activity during freeze-drying in 
microplates. B represents PEG 2000 and BC represents the interaction 
between PEG 2000 and lactose. Orange points demonstrate a positive effect 
while blue points represent a negative effect and green triangles represent 
centre point experiments 
 
3.3.3 Central Composite Face Designed Experiment for Optimisation 
Investigation 
Following analysis of results from the fractional factorial, PEG and lactose 
were identified as key factors for further investigation and optimisation.  Using 
random surface modelling a central composite face design was employed to 
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identify the optimal formulations based on the results identified in the initial 
screening investigation.  In this experimental design, all factors were varied at 
three levels, high middle and low, to accurately develop a model which would 
also include any curvature.  The design matrix for the optimisation is shown in 
Table 3.6 with the coded values shown in Table 3.5.  Runs 1, 5 and 9 contained 
identical formulations and represent the centrepoints of the design space 
investigated. The results from these experiments were used to develop a 
quadratic model of the system.  The accuracy of the model was assessed using 
ANOVA and the p-value was determined to be 0.0001 which again shows the 
model is statistically significant.  Therefore, any conclusions based on the results 
and the model could be considered valid and accurate. The results are plotted on 
the surface graph shown in Figure 3.4 which demonstrates the curvature present in 
the model.  It also shows that contrary to the initial conclusion based on Figure 
3.3, the optimum formulation involves the presence of lactose as well as PEG, for 
example, 2% lactose and 0.5% PEG will give slightly less retention of LDH 
activity than at 1.8% lactose and 0.4% PEG.  Thus the addition of excess PEG 
and/or lactose can actually be detrimental to maintaining LDH stability.  The plot 
shown is based on the model described in the following equation which can be 
used to find the optimum solution: 
 
Percentage Activity Retained = -64.25 +548.6[PEG] +88.32[Lactose] -
32.26[PEG][Lactose] -659.1[PEG]2 -24.69[Lactose]2 
Where [PEG] and [Lactose] are measured as percentage concentrations on a 
weight by weight basis. 
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Figure 3.3 Interaction graph from fractional factorial screening investigation 
showing combined effect of increasing the concentration of PEG 2000 from 
0%-0.5% with lactose concentration set at 0% (black line) and 2% (red line) 
upon retention of LDH activity during freeze-drying in microplates, where 
all other factors are set to 0% concentration. The confidence intervals are set 
to 95% and demonstrate the region where one could expect to see the result 
appear 95% of the time. However the mean of a range of experiments would 
lie in the centre of the intervals. 
 77 
 
Figure 3.4 Surface plot showing the effect of varying PEG 2000 (x-axis) and 
lactose (y-axis) concentrations, upon the retention of LDH activity (z-axis) 
after freeze-drying. 
 Luthra et al (85) have shown recently that LDH can be stabilised by 
lyoprotectants which promote hydrogen bonding or which form good glassy 
states. Lactose would be expected to demonstrate the former.  PEG has also been 
shown to maintain stability through cryoprotection of LDH during the freezing 
stage (75).  
 
During the freeze-thawing of proteins, PEGs are thought to act as a 
cryoprotectant through several potential mechanisms that also depend on the PEG 
molecular weight.  For LDH these included non-specific binding of PEG to the 
protein, and delayed ice crystallization during freezing, but did not include their 
preferential exclusion from the protein surface, or the suppression of protein 
aggregation (75).  Non-specific binding of PEG to the protein surface could 
provide a protective shell that minimises protein:protein interactions, but it may 
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also result in a more ordered water structure around the protein which would 
reduce the nucleation of ice close to the protein surface (86).  During the 
resuspension of the lyophilised protein PEGs could potentially also act as 
chaperones that favour folding to the native state for partially denatured proteins, 
in addition to directly stabilising the native state as is often seen for proteins in 
solution (76). 
3.3.4 Verification of Optimal Freeze-Drying Formulation in Vials 
Having identified a region of optimum formulations using experiments in 
microplates it was important to verify that the predictions made by the model 
were verified upon scale up to vials. The vials containing the formulations shown 
in Table 3.7 underwent the lyophilization cycle shown in Table 3.8. Table 3.7 
shows the predicted activity retention by the model together with the 95% 
confidence intervals. The results were all close to the predicted mean and within 
the predicted confidence intervals thus verifying the accuracy of the model.  
 
Table 3.8 Lyophilization cycle used for pilot scale freeze-drying in 22mm 
vials. 
3.4 Conclusions 
The purpose of this investigation was to develop a generic framework for 
the rapid identification of an optimum formulation for the purposes of maintaining 
activity during a lyophilization process.  It further aimed to show the benefits of 
using microwells for optimisation in order to minimize the quantity of material 
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needed to carry out sufficient experiments.  In order to conduct a 2 level 
investigation of 7 excipients followed by a 3 level investigation of 2, one would 
have to conduct 27+32=137 experiments using an OFAT approach, which 
including repeats would have used grams of material and would have been time 
consuming.  Furthermore without appropriate statistical analysis it would not be 
possible to identify interactions.  The approach detailed here required a total of 30 
experiments which is a reduction of approximately 22% and used approximately 
13 micrograms of LDH. 
 
This investigation identified lactose and PEG as effective excipients in 
maintaining LDH stability during freeze drying.  Lactose is thought to stabilise 
LDH through the promotion of hydrogen bonding (85).  PEGs can act as a 
cryoprotectant for LDH by delaying ice crystallization during freezing, and also 
by forming non-specific interactions with the protein that then minimise 
protein:protein interactions (75), while also reducing the nucleation of ice close to 
the protein surface (86). 
 
The DoE model generated in this study predicted a formulation which 
retained almost 100% of the activity, and was then shown to be correct on scale 
up to vials.  Were this method to be adopted in an industrial process one could 
develop a formulation and drying cycle more quickly than by current methods.  
Furthermore, the model could be used for process validation to determine the 
upper and lower limits of the operating parameters. 
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Chapter 4. Rapid Identification and Optimisation of Freeze 
Drying Formulation for Granulocyte Colony Stimulating Factor 
4.1 Introduction 
The previous chapter demonstrated how factorial design can be combined 
with ultra scale down to provide a rapid screening and optimisation platform 
technology to identify a formulation for the lyophilization of biopharmaceuticals. 
The protein under investigation was lactate dehydrogenase, a model protein that is 
reasonably stable under normal conditions. It was therefore necessary to apply this 
platform to a challenging protein that is used as a therapeutic and is known for its 
instability and difficulty to freeze dry, so that the general applicability of the 
techniques can be demonstrated. 
  
Granulocyte colony stimulating factor (G-CSF) is a therapeutic protein 
marketed under the brand name Neupogen. Chemotherapy can result in 
neutropenia, a haematological disorder characterised by an abnormally low 
number of neutrophils in the blood stream. Human G-CSF can be manufactured 
recombinantly as a non-glycosylated form in E. coli which is effective in treating 
patients suffering from neutropenia (87). Recombinant Human G-CSF (RhG-
CSF) is a monomeric cytokine consisting of a four alpha-helical bundle (88, 89) 
and whose conformational stability in solution is greatest at pH 4.0, but which 
aggregates within days at pH 7.0 (88).  Consequently, RhG-CSF is typically 
formulated as a liquid only at pH 4.0 and injected directly into patients.  Typical 
liquid formulations for G-CSF at up to 500 µg/ml include acetate or succinate 
buffer at pH 4.0, a stabilising detergent such as Tween 20 or Tween 80, osmolytes 
 81 
such as sorbitol, mannitol or trehalose, and human serum albumin as a bulking 
agent to block and prevent interactions of the G-CSF with vial surfaces (90, 91).  
 
The difficulties associated with freeze drying solutions at pH 4.0 such as 
concentration effects and pH shifts contribute towards the aggregation of G-CSF 
during lyophilization and the observed loss of activity on resuspension. There is 
evidence that the glycosylated eukaryotic expressed material may be successfully 
lyophilised (92). The therapeutic is marketed as a liquid formulation (93) and 
stored at 2 – 8 oC. Liquid formulations are generally preferred in industry as they 
provide the product in the form in which it will be used and remove potential 
errors from resuspension protocol variations. 
 
Biological medicines differ from small molecule APIs in that the materials 
are not capable of complete characterisation by chemical means alone and so 
potency is often assigned by reference to a recognised reference preparation. Such 
materials are typified by the WHO International Standards 
(www.who.int/biologicals). Many of these materials are lyophilized to facilitate 
distribution and their GCSF standard 88/646 that is lyophilised  is a glycosylated 
eukaryotic form. There is a requirement for companies to stock standards of their 
products for quality control purposes. These standards are used as the baseline for 
all assays conducted on product material. As such, a standard does not need to 
have a therapeutic concentration at dosage levels for the active protein but rather a 
concentration at which an appropriate assay can accurately measure its activity. 
This investigation looks at applying the methods from the previous chapter to a 
challenging therapeutic protein to develop a lyophilized biological standard of 
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bacterially expressed G-CSF. Such a standard must maintain biological activity 
throughout the lyophilization process and then maintain its activity on long term 
storage. Finally, the formulation should preserve the G-CSF in its unaggregated 
state for a reasonable period of time upon resuspension into an assay buffer such 
as PBS at pH 7.0. 
 
4.2 Materials and Method 
4.2.1 Materials 
 Trehalose, Phenylalanine, media, Sodium Phosphate (monobasic and 
dibasic) and L-Histidine were all purchased from Sigma-Aldrich Chemical Co 
(Poole, UK). Mannitol and Arginine were purchased from VWR (Leicestershire, 
UK), Sucrose from FSA (Loughborough, UK), Tween 20 from Bio-Rad 
Laboratories (Hercules CA, USA) and Human Serum Albumin (20% w/w) (HSA) 
was obtained from Grifols (Barcelona, Spain). G-CSF was provided by NIBSC 
supplied to them as a biosimilar for research/evaluation purposes from an Indian 
biopharmaceuticals company and was obtained in solution at 1mg/ml at pH 4.0. 
RPMI – 1640 Media for the cell based assay was purchased from Sigma – Aldrich 
Chemical Co (Poole, UK) and the tritiated thymidine was purchased from Perkin 
Elmer (Boston, MA, USA). The assay was carried out using a GNFS – 60 cell 
line.  The 96 – well microplates were purchased from Greiner (Greiner, 
Stonehouse UK) and the bottom lips trimmed off such that the bottom of the wells 
rested directly on the freeze drier shelves. 
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4.2.2 GNFS-60 bioassay 
 GCSF activity was assayed using an in-vitro cell growth activation assay. 
Serial dilutions of G-CSF were prepared and cell growth was measured by 
scintillation count of tritiated thymidine as has already been described (112, 113). 
Each sample was assayed in duplicate on a microtitre plate and compared to a 
control sample of G-CSF which had not undergone lyophilization. Solutions 
containing G-CSF were diluted to 10 ng/ml G-CSF in fermentation media. 160 µL 
media were pipetted into each well in the top row of a 96-well microtitre plate. 
The rest of the wells on the plate were filled with 100 µL media. 40 µL of solution 
containing 10 ng/ml G-CSF was then pipetted into the top well giving a final 
concentration of G-CSF in the top row of 1ng/ml. A serial dilution was then 
performed down the plate so that subsequent rows contained 500, 250, 125, 63, 
31, 16, and 8 ρg/ml G-CSF. 100 µL of media containing 105 cells/ml was then 
added to each well and the plate was incubated at 37 0C for 48 hours. Each well 
was then pulsed with 50 µL tritiated thymidine and media and incubated for a 
further 4 hours at 37 oC. The plate was then harvested onto a filter mat, dried and 
sealed in a plastic bag containing a scintillant. This was then counted on a Triluz 
1450 Microbeta Scintillation Counter (Perkin Elmer, Massachusetts USA) to give 
a final cell count. This count was plotted and parallel line analysis was then 
conducted using proprietary software to give a relative potency of the sample 
under test relative to the untreated G-CSF. 
 
4.2.3 G-CSF freeze-drying and activity measuring in microplates 
As described in the previous chapter, a fractional factorial design was used 
to screen seven excipients to identify which excipients best preserve G-CSF 
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during freeze drying. A categorical factor – buffer type – was also included to 
assess which buffer performed best or whether a buffer was even necessary. The 
ranges for the excipient concentrations investigated are shown in Table 4.1. G-
CSF (100 ng/ml) was prepared in 200µL aliquots containing the excipients and 
buffers shown in Table 4.2. Due to potential edge effects all outside edge wells 
were filled only with buffer.  Microplates were placed in a Virtis Genesis 25EL 
freeze dryer (Biopharma Process Systems, Winchester, UK) and the samples 
freeze dried under the conditions shown in Table 4.3. 
 
 
Table 4.1 Excipients and concentration ranges investigated in the factorial 
screening experiments 
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Table 4.2 Percentages by weight of excipients present in initial all factorial 
screening formulations for freeze-drying of G-CSF in microplates 
 
Table 4.3 Lyophilization cycle used for ultra scale-down experiments in 
microplates 
The freeze-dried protein cake was then resuspended in d’H2O and 
subsequently diluted into media for assaying as described in section 4.2.2. 
 
Following the initial investigation the optimisation experiment was 
developed in Design Expert as described in Section 3.3.3 using random surface 
modelling to produce a central composite faced design where each factor was 
investigated at three levels. The recipes used are shown in Table 4.4. 
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Table 4.4 Percentages by weight of all the excipients present in the 
optimisation investigation for freeze drying G-CSF in microplates 
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4.2.4 Verification of Optimal Freeze-Drying Formulation in Vials 
In order to validate the model, three formulations at two pH’s were 
lyophilized and are described in Table 4.5. 
 
Table 4.5 Formulation recipes for model validation experiments in 22mm 
vials 
To further demonstrate that no buffer is required a comparison was made 
between two identical formulations in different solvents – histidine buffer and 
water and the recipes are shown in Table 4.6. 
 
Table 4.6 Recipes used to demonstrate effectiveness of water as solvent in 
vials 
All experiments were conducted using a 1 ml fill volume and lyophilized 
using the cycle shown in Table 4.7. Although the concentration of G-CSF was 
100 ng/ml throughout it was decided to see whether the optimum formulation was 
valid at 1 µg/ml as well. 
 
Table 4.7 Drying recipe for validation experiments in vials 
Finally, it was also necessary to demonstrate a lack of interference 
between the formulation and the bioassay. Unlyophilized G-CSF was formulated 
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and then assayed in the same manner, to identify potential differences between 
formulated and unformulated G-CSF and their impact on the assay itself. 
 
4.2.5 Stability of Liquid Formulated G-CSF  
The overall aim of freeze – drying biopharmaceuticals is to preserve them 
until needed by a medical practitioner. As such, although preservation of activity 
is important, it is also vital to know how long after resuspension the drug remains 
fit for use. It was decided therefore to investigate the liquid stability of G-CSF 
over a period of 7 days stored at room temperature. It is common for injectable 
drugs to be re-constituted in PBS so all formulations were prepared in PBS. One 
set was formulated and lyophilized, one set was formulated and left to stand and 
one set was formulated in plain PBS. The formulations were reconstituted or 
formulated on days 0, 3, 5 and day 7. All were then assayed at the same time on 
day 7 to ensure that day-to-day variations in the assay, due to differences in cell 
batches, were eliminated when comparing relative activities. 
 
4.2.6 Accelerated Degradation Study of Lyophilised G-CSF Formulations  
The purpose of lyophilization is to preserve the biopharmaceutical product 
in a state that is suitable for long term storage e.g. two years. To determine the 
long term stability of the freeze dried cake, samples were lyophilized and then 
stored at -20 oC, 4 oC, 20 oC, 37 oC, 45 oC and 56 oC. Accelerated degradation is a 
widely used method to rapidly assess the likely stability of biopharmaceuticals 
(96). These were assayed at 4 month and 6 month intervals and compared to a 
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lyophilized baseline kept at -70 oC to give Erying plots of the Arrhenius equation 
according to Equation 4.1. 
 
 
Equation 4.1 Erying equation where k is the reaction rate constant, T is 
absolute temperature, delta H is enthalpy of activation, R is gas constant, kB 
is the Boltzmann constant, h is Planck’s constant and delta S is the entropy of 
activation. 
4.3 Results and Discussion 
4.3.1 G-CSF Freeze Drying and Activity Measurement in Microplates 
Eight factors were initially chosen for investigation using a Design of 
Experiment (DoE) approach. Seven (excipient concentrations) were numeric and 
one (buffer type) was a categorical factor. As with LDH the purpose of this 
experiment was to rapidly identify which factors had a positive effect on 
maintaining the biological activity of G-CSF during lyophilization. The seven 
excipient factors chosen were trehalose, human serum albumin (HSA), mannitol, 
sucrose, Tween 20, arginine and Phenylalanine as detailed in Table 4.1. These 
were chosen because all are common excipients used as cryoprotectants and 
lyoprotectants in the industry, including for G-CSF. Trehalose and sucrose for 
example are very common excipients and the use of mannitol has been well 
documented due to its ability to crystallize well under acceptable conditions (97, 
98).  Likewise, the buffer options chosen were 30 mM Histidine Buffer and 
50 mM Phosphate Buffer both at pH 7.0 on the basis that they are two common 
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buffers used in liquid protein formulations (99). HSA is a plasma protein (100) 
which has been used in the past both to preserve active pharmaceutical ingredient 
activity and bulk out the cake (101, 102). Although pH shifts are known to occur 
during freezing with Phosphate Buffer (102, 103), it was decided that due to the 
relatively low concentration of buffer compared to the other excipients, such shifts 
would not cause significant  damage and the other components may even protect 
against damage occurring. 
 
The factorial design chosen was a fractional factorial design where each 
factor was varied at two levels. Twenty runs were required which included four 
centre point repeat experiments as detailed in Table 4.2.  Each formulation was set 
up in microplates and freeze-dried as described previously in Chapter 3.2.3.  
Samples were then resuspended in PBS and assayed for biological function in 
terms of the stimulation of 105 cells (Section 4.2.2) relative to a standard of 
unlyophilized G-CSF stored in the supplied formulation at pH 4 and 4 oC. 
 
Figure 4.1 Half Normal Plot of Screening Results 
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As described previously (Chapter 3.3.2), a Half-Normal plot is used to 
identify those factors and interactions that have a significant effect.  The Half-
Normal plot in Figure 4.1 shows clearly that only two factors influenced the 
preservation of activity of G-CSF during freeze drying.  The normal plot (or Half 
– Normal plot in this case) is a plot of actual data against predicted data. The 
prediction is based on the assumption that all factors are non significant and as 
such the outcomes should be a normal distribution around zero. Therefore any 
outcome that does not fall within this normal distribution must have a non – zero 
outcome and must be significant. This is seen by the deviation from the straight 
line which represents the normal distribution around zero. Here the two most 
significantly influential factors were HSA and Tween-20. It was interesting to 
observe that the type of buffer used had no effect at all on the G-CSF as this has 
often been found to be important for stability at pH 4.0 (104), and also because G-
CSF stability is known to be pH sensitive. It is possible that the presence of HSA 
and/or Tween-20 have some buffering effect such that they were sufficient to 
negate the requirement for an additional buffer. Clinical grade HSA often contains 
trace levels of buffer from its preparation and it is commonly used as a stabilizer 
in protein formulations for a number of reasons. Its amphiphilic properties make it 
suitable as an additive to inhibit adsorption of the protein onto the wall of the 
vessel, which due to the low concentration of G-CSF present in these formulations 
was likely to be important. HSA is also a known lyoprotectant (105). Similarly 
Tween-20 is also a surfactant and can suppress aggregation of proteins in solution.  
 
Having identified the significant effects, the DoE software was then used 
to build a model based on these results and the model can be assessed for its 
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statistical significance through ANalysis Of VAriance  (ANOVA). The key 
figures from ANOVA of the model are the p-value which ideally should be less 
than 0.05 and the signal to noise ratio or F Value which ideally should be as high 
as possible. The model has a p-value less than 0.0001 and an F Value of almost 
24. Having established the mathematical model is statistically significant it can be 
used to plot the graph shown in Figure 4.2 which shows the maximum achievable 
activity preservation is attained at 2% HSA and 0.1% Tween-20. The linear nature 
of the graph however suggested that an optimum had not been found and that the 
range of concentrations of HSA and Tween-20 should both be increased. 
Therefore the ranges were increased up to 5% and 0.5% respectively, for the 
subsequent optimisation study. 
 
Figure 4.2 Contour graph showing how activity varies with Tween-20 (%v/v) 
and HSA concentrations  
 
(%w/w) 
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The type and addition buffer was shown to be unimportant in terms of the 
preservation of G-CSF activity, potentially due to the inherent buffering potential 
of the HSA, Tween-20 or possibly even the G-CSF itself. This can be seen as a 
serendipitous result as buffers themselves can often cause problems during freeze 
drying due to pH shifts or salt concentration effects. It was therefore decided to 
conduct the optimisation study without additional buffer with the final 
formulations checked to make sure they were at pH 7 (51, 106). However, current 
commercial liquid formulations for G-CSF are kept at pH 4 at between 2 - 8 oC so 
it was also decided to conduct the optimisation study in water at pH 7 and also for 
comparison in acetate buffer at pH 4. 
 
Due to the categorical nature of pH as a factor, the results of the 
optimisation investigation are split into two graphs with one showing formulations 
dissolved in demineralised water and the other showing formulations dissolved in 
acetate buffer at pH 4. The final activity results obtained from these two 
investigations are shown in Figure 4.3 and Figure 4.4 respectively. 
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Figure 4.3 Contour graph showing the effect of varying Tween-20 and HSA 
on the retention of G-CSF activity in water at pH 7 
 
 
Figure 4.4  Contour graph showing the effect of varying Tween-20 and HSA 
on the retention of G-CSF activity in acetate buffer at pH 4 
The response curve shown in Figure 4.3 confirmed the results of the initial 
screening investigation in that it was now clear that an optimum region existed 
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outside the range of concentrations for HSA and Tween-20 used initially in the 
screening experiments. As with LDH excess reagents do not lead to an increase in 
activity retention but the concentrations must be limited to within the region 
bounded by the 100% contour. An  optimum formulation for G-CSF at 0.1 ug/ml 
in water at pH 7 was found to be 0.3% (v/v) Tween-20 and 3.5% (w/w) HSA. It is 
worth noting that no liquid (or freeze-dried) formulations have been previously 
identified at pH 7, though normally for pharmaceutical applications, the G-CSF is 
stored as a liquid at higher protein concentrations, typically 100-500 ug/ml). 
 
It is interesting to note that even though G-CSF is most stable in liquid 
formulation at pH 4 (107). This was not found to be the case during freeze drying 
at the G-CSF concentration used in this study. It is not possible using Tween-20 
and HSA, to achieve 100% retention of activity using a solvent that is at pH 4 
initially. This is surprising given that G-CSF is more stable in liquid formulations 
at pH 4 than at pH 7. The difference in freeze-drying could be due to localized pH 
shifts and concentration effects, for example when ice crystals form during 
freezing and exclude the buffer salts, other excipients and G-CSF. Due to such 
effects and also their additional cost a formulation that does not require a buffer 
would be advantageous to an industrial bioprocess.  At pH 4, an optimum of 
approximately 70% activity was obtained for  0.15% (v/v) Tween-20 and 3.5% 
(w/w) HSA, though a second optimum may exist at >0.5% v/v Tween-20 which 
could potentially achieve greater than 70% retention of activity.   
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4.3.2 Verification of Optimal Freeze-Drying Formulation in Vials 
Having identified the optimal region of operation it was necessary to 
verify that the predictions made by the model remained true on scale up to the 
types of vials to be used in the creation of freeze-dried biological standards. The 
formulations for the optimum and a range of sub-optimal conditions described in 
Table 4.5 were made up to 1 ml per vial, filled and freeze dried using procedure 
shown in Table 4.7. The results, as shown in Table 4.8, demonstrated a high level 
of accuracy for the model with the predicted values closely matching the trend for 
the experimental values, thus verifying the model. The actual experimental results 
were all within 2% of their predicted values and well within the confidence 
interval ranges. The model was shown to be highly accurate with the actual results 
within 2% or even 1% of their predictions in runs 2 and 3. Bearing in mind the 
variability between different runs of the same assay was often up to 20%, this was 
a good result. 
 
Table 4.8 Formulation recipes and results for model validation experiments 
 To further verify that no additional buffer was required for the freeze-
drying of G-CSF at pH 7, a comparison was made between two identical 
formulations in histidine buffer and water as detailed in Table 4.6 (Section 4.2.4).  
The relative activities retained for samples resuspended after lyophilization, 
across five repeat vials each containing these formulations, were 110% and 108% 
for water and histidine respectively. The respective percentage errors were 8% 
and 7%. It can therefore be concluded that there was no requirement for a buffer 
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in addition to the excipients present and that the samples, which are at pH 7, must 
be sufficiently self-buffering at this concentration of G-CSF. 
 
4.3.3 Effect of formulation at higher G-CSF concentrations 
The aim of this experiment was to identify a formulation suitable for 
lyophilizing G-CSF for use as a biological standard required at the relatively low 
concentration of 100 ng/ml. However it would be useful to know whether this 
formulation had the potential to stabilise G-CSF at the concentrations typically 
used in pharmaceutical products. Therefore the optimum formulation found here 
was made again but with 1 µg/ml G-CSF and then lyophilized as previously. This 
formulation gave 85.5% ± 20.5% activity retention using the cell-based assay, 
suggesting that the formulation could potentially be sufficient for use in 
manufacturing G-CSF for medical use. 
 
It is possible that although the concentration of Tween-20 and HSA within 
the well is extremely low, their concentrations relative to G-CSF remain constant. 
Whatever protection mechanism these excipients perform on the G-CSF during 
freeze drying it would appear they continue to protect the protein in liquid too as 
was investigated further in section 4.3.5. 
 
4.3.4 Effect of optimum formulation conditions on activity assays 
It was possible that the relatively high levels of Tween-20 in the optimum 
formulation found above could have interfered with the growth of the cell line in 
the assay even though the highest concentration of Tween-20 in any well would 
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not exceed 0.003%. Therefore it was important to verify that the formulation was 
not having an apparent stabilising effect due to altering the response to the assay 
itself. To achieve this, two samples were prepared, one sample contained G-CSF 
at 100 ng/ml in a formulation containing 0.28% Tween-20 and 3.54% HSA in 
water. The other sample contained G-CSF at 100 ng/ml prepared in RPMI – 1640 
Media. Both were then assayed using the same method in Section 4.2.2, and the 
results can be seen in Figure 4.5.  
 
 Although there is a slight difference between the two curves the results 
show that Tween-20 and HSA do not have any significant effect on the growth of 
the cells that would account for the optimum formulation effects.  The two curves 
give a relative activity of the formulated to unformulated G-CSF of 110 %, which 
is much smaller than the difference in activities observed during freeze-drying due 
to the formulations remaining constant. Whatever protection mechanism these 
excipients perform on the G-CSF during freeze drying it would appear they 
continue to protect the protein in liquid too as was investigated further in section 
4.3.5. 
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Figure 4.5 Potency assay curve for formulated and unformulated G-CSF 
 
4.3.5 Liquid stability experiment 
Throughout this investigation assaying of the G-CSF was carried out 
within a short time span of resuspension of the freeze dried solid. The current 
liquid formulation prevents aggregation of the protein for at least two years at 
5 oC and even at room temperature the amount of aggregation is minimal. It was 
necessary to determine if the formulation that maintained activity and structure 
during freeze drying would do so in solution as well and for how long. It was 
further necessary to determine whether the protein had been damaged slightly 
during freeze drying in such a way as to result in a less stable product. Finally an 
understanding of the stability of the G-CSF in liquid form within this formulation 
would help develop an understanding of how these excipients protect the protein. 
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Figure 4.6 is the result of the experiment into the stability of G-CSF in solution.  It 
is immediately apparent that G-CSF in PBS alone is unstable and denatured 
rapidly. In the time taken to formulate the G-CSF in buffer and take it into the 
assay it lost 60% of its biological activity. This may however have been due to 
irreversible binding of the G-CSF to the walls of the vessel in which it was 
formulated. This problem is overcome through the presence of HSA which 
preferentially binds to the material either by better binding mechanisms or simply 
through the higher concentration of HSA relative to the G-CSF. 
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Figure 4.6 Liquid stability experiment 
This hypothesis could also explain why the relative concentrations of the 
formulated G-CSF were approximately 60% higher than the control sample taken 
directly from the liquid formulation. The G-CSF in the control sample is taken 
from the liquid formulation container at a concentration of 1 mg/ml and diluted to 
1 ng/ml in cell media. The G-CSF in the other samples were taken from 1 mg/ml 
and diluted straight into PBS containing HSA and Tween 20. Any potential 
binding sites would have been blocked by the HSA. The Tween 20 could then 
wrap around the protein and prevent aggregation with other protein molecules. 
The assay is also prone to errors both on behalf of the operator and by the nature 
of the assay itself so the single unexpected point on the graph can be attributed to 
error. 
 
One can conclude from Figure 4.6 that while G-CSF in PBS alone 
aggregated almost immediately and loses all activity within three days, G-CSF in 
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Tween-20 and HSA can sit on the shelf for a week without losing biological 
activity even if it was lyophilized first and then resuspended. As such a 
formulation containing HSA and Tween-20 in concentrations determined using 
Figure 4.3 can be relied upon to give a stable formulation.  
 
4.3.6 Accelerated Degradation Study of Lyophilised G-CSF Formulations  
Having developed this systematic approach to optimising 
biopharmaceutical formulations and having then applied it to the example of G-
CSF formulated as a biological standard it was necessary to ensure the 
formulation is fit for purpose. Here the aim was to have a dried standard that 
could be kept for two years with minimal loss of activity. As such it was 
necessary to gather some data regarding the long term shelf life of the finished 
product. Accelerated degradation studies involve leaving vials of lyophilized 
material at a range of temperatures in order to assess their stability. Vials were 
stored at -20 oC, 4 oC, 20 oC, 37 oC, 45 oC and 56 oC. These were then assayed at 
4 month and 6 month intervals and compared to a lyophilized baseline kept at -
70 oC to give Erying plots of the Arrhenius equation. Two lyophilized vials were 
further assayed immediately after lyophilization to ensure the entire batch still had 
100% of their original activity and had not become contaminated during the 
process (contamination can interfere with the assay and prevent reliable results). 
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Figure 4.7 Chart showing percentage activity retained by the freeze-dried 
formulation at pH 7 after storage at different temperatures 
As Figure 4.7 demonstrates, little activity is lost for temperatures up to 
room temperature. Thereafter at higher temperatures the protein starts to degrade 
suggesting that it is quite a heat sensitive labile protein structure.  The extent of 
degradation is not proportional to temperature but rather indicates that the 
degradation may follow an Arrhenius dependence typical of chemical reactions.  
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Figure 4.8 Erying plot of four and six month deg studies shown in blue and 
pink respectively 
By converting the data to give an Eyring plot as shown in Figure 4.8, and 
averaging the data, it was possible to estimate the product shelf life at various 
temperatures. This is shown in Table 4.9 which shows that at room temperature 
losses of just over 10% can be expected. This is not therefore an ideal formulation 
as regards long term storage at room temperature (typically up to 2 years).  
However it is important to remember that this formulation was never optimised 
for long – term storage and so if storage was included as a factor in the DoE, then 
the ideal windows of operation for such a formulation could potentially be 
obtained. 
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The Eyring plot in Figure 4.8 also show that the two decay lines fit well to 
a straight line, which is significant as it demonstrates that protein degradation is 
only occurring via one chemical mechanism, or at least that the set of chemical 
mechanisms do not change relative to each other with temperature.  Mechanistic 
changes tend to result in curved or kinked Eyring plots where the two mechanisms 
have different activation energies.  The linear relationship is important as it means 
that accelerated degradation studies at higher temperatures, accurately reflect the 
nature of the much slower degradation at lower temperatures.  Therefore, the 
accelerated studies are a good mimic of long term degradation. 
 
Table 4.9 Estimated shelf life of 100 ng/ml G-CSF lyophilized in Tween-20 
and HSA at pH 7 and various storage temperatures 
 
4.4 Conclusions 
Currently the processes by which formulations for lyophilization are 
chosen are primarily decided via empirical methods. There exists a need for a 
systematic approach to determining which excipients are most suitable. One 
approach to date has involved developing a deeper scientific understanding of the 
interaction between the protein and the excipients as well as an understanding of 
how the formulation responds to freeze drying (31, 108, 109). However the 
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information gained from analyzing the protein and its structure will still be 
insufficient to allow the accurate determination of which cryoprotectants and 
lyoprotectants will work. 
 
The approach taken here has been to develop a systematic method by which one 
can quickly identify which excipients have a positive effect and which have a 
negative or zero effect on preserving biopharmaceuticals with confidence. The use 
of factorial design also allows the investigator to identify possible interaction 
effects between excipients. A scientific understanding of the protein molecule is 
still necessary to identify a set of excipients which are likely to work. However, a 
factorial designed experiment remains the only way to identify and then optimise 
a formulation. 
 
The use of microtitre plates has two advantages. The use of ultra scale – 
down has already been identified as an excellent method of process development 
investigations using minimal material. The use of automation combined with ultra 
scale down in areas such as chromatography, filtration and fermentation would 
require modification or retro fitting of existing equipment to conduct these 
processes. However, the use of a Tecan or HP robot simply to mix and blend the 
formulations created via the factorial design software would increase the 
efficiency of the method immediately. A micro freeze drier, which is a relatively 
simple piece of kit to manufacture, would increase the viability of this method 
even further (110). As things stand most scientific establishments have ready 
access to microtitre plates and robots and the platform technology detailed here 
could readily be adapted for use in industry immediately.  
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We have shown through the use of a model protein and an industrially 
manufactured biopharmaceutical that factorial design coupled with ultra scale 
down can rapidly identify and optimise formulations for freeze drying to preserve 
the biopharmaceutical product. The results are easily transferable to 
manufacturing scale vials. The data produced can be used to develop 
mathematical models with defined degrees of accuracy vital for validation work. 
The next chapter will deal with the use of factorial design for development of the 
lyophilization cycle and will also assess the viability of microtitre plates for such 
work. 
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Chapter 5. Development of a Correlation Model for the 
Lyophilization Cycle Through the Use of Factorial Design 
5.1 Introduction 
 So far this thesis has looked solely at formulation development, with the 
aim to develop a systematic approach to the creation of viable formulations for the 
lyophilization of biopharmaceuticals.  The aim of such an approach would be to 
maintain protein structure and activity throughout the freeze-drying process.  This 
Chapter looks at the development of the freeze-drying cycle itself to result in a 
lyophilized protein cake with a solid appearance and moisture content of below 
1%.    
While there is no doubt that the cycle parameters and final moisture 
content impact on the final activity of the protein (111), due to the nature of the 
investigation outlined herein and the variability of protein assays, preservation of 
activity was deemed of secondary importance to appearance and moisture content.  
Indeed it is almost certain that there exists an interaction between formulation and 
cycle parameters, for example if one freeze-dries mannitol too quickly vial 
breakage is a common result (112).  Using a factorially designed experiment to 
understand this interaction would be a valuable investigation but it was felt that 
the initial step towards such an investigation would be to isolate formulation and 
cycle parameters and investigate each factor independently by assessing the effect 
of formulation on activity and cycle design on cake quality and moisture content. 
  
From both an operational and regulatory point of view an understanding of 
what is happening during a process is required.  This is particularly true of 
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lyophilization which is often the final process the biopharmaceutical goes through 
before it reaches the end user.  Furthermore from a process development point of 
view it is difficult to design a process without knowledge of what is happening 
during that process.  Despite this, the process development of lyophilization is 
only slightly less empirical than the formulation development (72).  The process is 
generally split into three stages namely freezing, primary drying and secondary 
drying.  The freezing stage can also contain annealing stages whereby ice crystal 
size is encouraged to grow by holding the frozen solid at temperatures that exceed 
the glass transition temperature (12), but during the initial stages of process 
development it is often necessary to simplify as much as possible.  
 
Mathematical models are commonly used in the design of processes in 
every industry such as bioprocessing, finance or construction.  Mathematical 
modelling of heat transfer to the vial during lyophilization has previously been 
carried out (77).  Furthermore, Boss et al (113) put forward a mathematical 
solution for modelling the freeze drying process.  Their model requires an initial 
investigation to empirically determine model parameters such as cake density and 
porosity.  One would also probably require a computer programme to calculate 
optimum cycles based on their model. 
 
While their model has many benefits and is a massive step forward in 
process development for lyophilization cycles, each formulation has different 
characteristics in terms of densities, porosities etc.  The lyophilization cycle itself 
will also affect those characteristics.  Freezing more rapidly and with no annealing 
step typically results in a denser cake with lower porosity than a material frozen 
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slowly.  This is due to differences in the size of the ice crystals formed during the 
freezing step.  Vials tend to freeze from the bottom up resulting in the non-
uniform morphology of ice crystals and the resulting cake structure (114, 115).  
These will result in deviations from a model system.  Additionally, the existing 
models cannot predict occasions where the cake collapses.  Although it can be 
generalised that a collapsed cake will often have higher residual moisture content, 
it does not follow that by a cycle determined by a model to result in a cake with 
low residual moisture would result in a uniform solid cake structure.  For 
example, a model may suggest a high pressure difference and high temperature to 
drive the process forward as fast as possible.  However, the resulting presence of 
high levels of protein on the surface of the cake can form a skin which “bursts” 
under the pressure of the water vapour causing a collapsed cake. 
 
This investigation aimed at developing an approach that was generic in its 
method and application but that would result in a product specific result every 
time, in order to determine the optimum cycle parameters to minimize residual 
moisture content while guaranteeing the formation of a freeze dried cake. The aim 
of such an approach is to put the controller in a position whereby they understand 
their system allowing them to demonstrate Quality by Design (QbD). By utilising 
such knowledge the user is able to state with conviction what is occurring in their 
process. Furthermore, accidents such as vacuum loss or shelf temperature 
variations may not necessarily result in the destruction of the product batch within 
the drier if the operator is able to continue the process utilising the QbD to ensure 
the resultant product meets the required specifications. 
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5.2 Materials and Methods 
PEG (MW 2000), Sodium Pyruvate, Sodium Phosphate (monobasic and 
dibasic) and Lactate Dehydrogenase (from Lactobacillus leichmanii) were all 
purchased from Sigma-Aldrich Chemical Co (Poole, UK). NADH was purchased 
from Calbiochem (Nottingham, UK), lactose from VWR (Leicestershire, UK). 
LDH (282 U/mg) was purchased as a lyophilized powder and was resuspended for 
baseline assaying in 100 mM phosphate buffer at pH 7.0 or for lyophilization in 
50 mM phosphate buffer at pH 7.0 and diluted to the desired concentration.  
 
5.2.1 Determination of residual moisture content 
Residual moisture analysis was performed using a coulometric Karl 
Fischer (Mitsubishi CA-100, A1-Envirosciences, Luton, Bedfordshire, UK) on 
three samples of each run. The coulometer performance was checked before 
assaying the products using a water standard (Solution P, A1 Envirosciences) with 
a  value of 180-210 µg water per 50 µL injection with a CV of <5%.  
 
5.2.2 Determination of the glass transition temperature of LDH formulated 
in phosphate buffer, 0.41% PEG and 1.7% Lactose using modulated 
differential scanning calorimetry 
Modulated Differential Scanning Calorimetry (mDSC) was carried out 
using a Q2000 DSC (TA Instruments, Crawley, UK).   40 µL of the formulation 
was pipetted into a DSC pan, crimped closed and placed together with an empty 
reference pan on the autoloader. The sample was lowered to -90 oC at 10 oC/min 
then raised at a rate of 1.5 oC/min up to 25 oC with modulations at 0.23 oC every 
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60 seconds. Analysis was performed in Universal Analysis (TA Instruments, 
Crawley, UK) 
5.2.3 Determination of the Correlation Model for the Lyophilization Cycle 
for LDH 
A central composite face design was used with response surface modelling 
to develop a mathematical model to identify an optimum cycle design that 
minimized the residual moisture content while maintaining a good cake structure 
appearance.  To simplify the design no annealing stage was used, ramping rates 
were fixed at the limits of the machine, parameters such as temperature and 
pressure were kept constant within each stage and the process was split into a 
freezing, primary drying and secondary drying stage.  As the driving force during 
primary drying can be expressed as the difference between vapour pressure and 
chamber pressure (14) the chamber pressure during the primary drying phase is 
expressed as a percentage of the vapour pressure at that shelf temperature.  The 
factors and their ranges are shown in Table 5.1.  
 
Table 5.1 Factors and ranges investigated to develop a model 
A central composite face design was developed using Design Expert 7 and 
was used to vary each factor between its maximum, minimum and mid point.  A 
full list of all the combinations used is shown in Table 5.2.  Each run involved the 
lyophilization of 10 vials containing 1 ml of solution containing 0.05 U/ml LDH, 
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1.7% Lactose and 0.41% PEG in pH7 50 mM Phosphate Buffer.  Following 
lyophilization, all the vials were examined visually to determine the quality of the 
cake.  The cake quality was qualified as simply either good (1) or poor (0).  The 
presence of any vial containing a collapsed cake other than the vial holding the 
thermocouple resulted in a score of 0.  Triplicate vials were then assayed for 
residual moisture content using Karl Fischer Titration.  Following incubation at 
room temperature for at least two weeks, duplicate vials were assayed using 
NADH and pyruvate on a plate reader as has already been described in section 
3.2.3.  
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Table 5.2 Lyophilization cycles used to determine the empirical model 
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5.2.4 Residual Moisture Analysis Using Karl-Fischer Titration 
Residual moisture analysis was performed using a coulometric Karl 
Fischer (Mitsubishi CA-100, A1-Envirosciences, Luton, Bedfordshire, UK) using 
Aquamicron catholyte and anolyte reagents (Mitsubishi, Japan) within a Plas Labs 
(A1 Safetech, Luton, UK) nitrogen dry box maintained at low relative humidity 
(<300 ppmv water vapour as measured by dew point hygrometer DS2000 – 1, 
Alpha Moisture Systems, Bradford, UK). Three samples from each run were 
opened within the dry box, reconstituted with anolyte which was then returned to 
the coulometer. The coulometer performance was checked before assaying the 
products using a water standard (Solution P, A1 Envirosciences) with a  value of 
180-210µg water per 50µL injection with a CV of <5%. 
5.2.5 Validation of the Correlation Model 
Having attained a mathematical model for predicting the residual moisture 
and cake structure of the freeze dried product it was necessary to demonstrate that 
it correlated well with real life examples.  Five different cycles were selected and 
repeated in triplicate to assess the accuracy of the model.  One cycle prediction 
was outside the limits of the initial investigation to determine how accurate the 
model was for predictions beyond the limits of the data obtained.  
 
5.3 Results and Discussion 
5.3.1 Determination of the glass transition temperature of LDH formulated 
in phosphate buffer, 0.41% PEG and 1.7% Lactose 
Differential Scanning Calorimetry (DSC) is routinely used to determine 
the glass transition temperature of formulated materials (116-121). The 
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thermogram of 0.5 U/ml LDH formulated in 50 mM phosphate buffer, 0.41% 
(w/w) PEG and 1.7% (w/w) lactose at pH 7.0 obtained by mDSC is shown in 
Figure 5.1 and demonstrates that an exothermic  (crystallization) event occurred at 
-15 oC. To allow for any errors in the monitoring of the shelf temperature and to 
take into account the heat transfer from the shelf to the vial, -16 oC was selected 
as the significant temperature above which collapse was expected during primary 
drying.  
  
Figure 5.1 mDSC thermogram of 0.41% PEG, 1.7% Lactose and 0.5 U/ml 
LDH 
5.3.2 Correlation Model for Residual Moisture Content 
A typical lyophilization cycle used is shown in Figure 5.2. 
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Figure 5.2 Lyophilization cycle for Run 2. As shown in Table 5.2, Run 2 
started with a 240 min freeze at -21 oC, then primary drying took place for 
360 mins at  – 21oC and 396 mTorr (60% of the vapour pressure of ice at – 21 
oC). Secondary drying was conducted for 360 mins at 15 oC and a pressure of 
65 mTorr. The pink, dark blue, light blue and brown lines represent product 
temperature, shelf temperature, chamber pressure and condenser 
temperature respectively 
 
During primary drying, the water present as ice sublimes to leave a solid 
with approximately 10% w/w moisture content.  This remaining water is released 
during the secondary drying stage.  The presence of bulk water allows the protein 
product to remain biologically active but also provides potential conditions for the 
protein to aggregate or unfold.  By removing more than 99% of the bulk moisture 
content the final product is immobilized in the cake structure and less likely to 
decompose.  The residual moisture content can be assessed using Karl Fischer 
titration.  Following freeze drying, three vials were assessed for residual moisture 
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content using a Karl Fischer titration cell and the results averaged before input 
and analysis to determine a model.  The resultant model is shown in Equation 5.1. 
 
Equation 5.1 Correlation model for residual moisture content (MC = 
Moisture Content, F = Freezing, PD = Primary Drying, SD = Secondary 
Drying, t = time (mins), T = Temp (oC), P = Pressure (%Vp at that 
temperature for PD and mTorr for SD) 
What is immediately apparent is that out of the eight factors from Table 
5.1 only five are shown to have a significant impact on the residual moisture 
content.  It would appear that as long as the freezing temperature is below the 
glass transition point of the material the actual temperature is insignificant.  In an 
industrial process a low freezing temperature is vital to avoid the occurrence of 
supercooling, which by way of example, demonstrates the importance of 
combining engineering knowledge as well as a good model.  
 
By inspection of the equation it is clear that the driving forces behind the 
rate of freeze drying are the chamber pressure during primary drying and the 
length of the secondary drying phase.  While the shelf temperature during primary 
drying has been ignored in the model, it is important to bear in mind that the 
chamber pressure during primary drying is expressed as a percentage of the 
vapour pressure of ice at the selected shelf temperature.  As such the shelf 
temperature has already been incorporated into the model as the primary drying 
phase chamber pressure is a derived factor rather than a base factor.  The shelf 
temperature during primary drying has been shown to be irrelevant in determining 
the rate of freeze drying on condition that the product temperature does not exceed 
 119 
the collapse temperature (78).  The product temperature is a far more important 
factor but no method for controlling the product temperature has been successful 
to date. 
 
The pressure difference between the vapour pressure on top of the ice front 
and the chamber pressure has previously been shown extensively to influence the 
rate of freeze drying (14, 78, 122).  In fact the fundamental modelling of freeze 
drying often uses the relationship shown in Equation 5.2.  A high chamber 
pressure results in a small pressure difference and a lower rate of sublimation 
which results in a higher moisture content.  As the term PDP (Primary Drying 
Pressure) in Equation 5.1 relates to a percentage of the vapour pressure at that 
shelf temperature, the term has in fact taken Equation 5.2 into account. 
 
Equation 5.2 Where: dm/dt = rate of sublimation, Po = vapour pressure of ice 
at that product temperature, Pc = chamber pressure and R = resistance to 
vapour flow 
 
The most significant factor in the model, seen in fact to be twice as 
important as the primary drying pressure, is the length of time of the secondary 
drying phase.  The secondary drying pressure, which was varied between 30 and 
100 mTorr, is shown not to have any effect at all.  In other words, there is no need 
to run the secondary drying phase below 100 mTorr as it will make little 
difference to the drying rate.  This is because the rate determining step during 
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secondary drying has been shown to be the diffusion of water through the solid 
(37, 122).   
 
Diffusion is the random migration of molecules from a region of high 
concentration to a region of low concentration and is defined by Brownian 
Motion. As such it is logical to state that the more time the particles have to 
migrate and the more energy in the form of heat inputted into the system, the 
greater the rate of diffusion of water particles. Pressure would not be expected to 
significantly impact on the rate of diffusion of vapour through the solid. The 
results from this experiment correlate well with those found by Pikal et al (37) and 
others.  
 
Pikal et al (37), showed that not only is chamber pressure not a significant 
factor during secondary drying but also discovered that the rate of drying during 
the secondary drying phase is initially high but then plateaus out.  High shelf 
temperatures can reduce the height of the plateau as confirmed by Equation 5.1.  
Therefore if the rate of drying plateaus and cannot be made to increase it is 
understandable that the length of time of the secondary drying phase is an 
important factor in minimizing residual moisture content.  
  
It is interesting to note that the length of time for which the product 
underwent freezing had a significant impact on moisture content.  The freezing 
period was varied between 0.5 hours and 4 hours.  It was expected that freezing 
for 0.5 hour at a temperature below the glass transition temperature of the product 
would be sufficient to freeze 1ml.  Furthermore as freezing is essentially a binary 
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state (either it is solid or liquid) it was not expected to influence residual moisture 
(although it may effect appearance as if it doesn’t freeze it will collapse).  
However the model shows that freezing time can have an impact on the residual 
moisture content.  This suggests that something must have been happening within 
the vial during the freezing stage – such as annealing. 
 
As has been shown previously (52, 225, 122, 123), freezing rate is also 
important.  By allowing the ice crystals time to grow in size one increases the pore 
sizes in the freeze dried cake when the ice sublimes.  A more porous structure 
allows sublimation to occur at a faster rate resulting in lower final residual 
moisture content. 
 
Finally the primary drying time is also seen to be a significant factor in 
reducing the residual moisture.  This is logical because 90% of the drying takes 
place during the primary drying and that takes time.  Furthermore there is some 
overlap between the primary and secondary drying stages and some evaporation 
and diffusion can still occur at the lower temperatures present during primary 
drying. 
 
5.3.3 Correlation model for cake structure 
Although the cake structure has few implications towards activity and 
quality of the product, manufacturers prefer the finished lyophilized product to 
have a cake with a solid appearance and little evidence of shrinkage.  This is 
generally assessed by eye by the operator and measured as either good or bad.  
For the model it was necessary to quantify this assessment and so was done by 
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awarding either a 1 for a good cake or 0 for poor cake.  The assessment was 
carried out on the batch rather than the individual vial such that if 9 vials had a 
good appearance and 1 vial had a broken cake, the batch was awarded a 0. This 
was because the aim of the model was to achieve 100% perfection or as close to 
perfection as possible. 1 collapsed cake in 10 is 10% which was deemed too high 
a failure rate.  To avoid bias on behalf of the operator, the majority of the samples 
were also assessed independently by the freeze drying staff at NIBSC. 
 
Technically one could argue that as a collapsed cake contains higher 
residual moisture content, cake structure is included in the moisture content.  
However this is not the case as a product could have very low moisture content 
and still have collapsed due to blow out or through drying too quickly.  
 
Following the assessment of sixty runs the results were processed by 
Design Expert 7 to produce the correlation model as shown in Equation 5.3. 
 
 
Equation 5.3 Correlation model for cake structure where: CS = Cake 
structure, T t and P are Temperature time and pressure respectively, 
subscripts F, PD and SD are freezing, primary drying and secondary drying 
phases 
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The impact of each factor can be assessed by its coefficient.  A high 
coefficient means that factor has a high impact on cake structure.  Except in the 
cases of freezing and primary drying temperatures, a positive coefficient means 
the factor increases the likelihood of a good cake structure and a negative one 
implies a decreased likelihood.  The reverse is true for freezing and primary 
drying temperature as the temperature itself is inputted as a negative value.  
Therefore we can order the factors in terms of their coefficients to determine the 
order in which they each influence a good cake structure as shown in Table 5.3.  
The fact that the freezing temperature and primary drying pressures have a 
quadratic relationship with the cake structure demonstrates that the optimum value 
for these factors lies within the experimental parameters.  
 
 
Table 5.3 Table of factors ordered by coefficient. The factors that have the 
highest positive impact on cake structure are listed in descending order 
 
The freezing temperature is seen to have the greatest impact on cake 
structure as it is at the top and bottom of Table 5.3.  It is necessary to assess the 
 124 
overall impact of freezing temperature within the system.  To do that one can 
make all the other factors constant and assume freezing temperature is the only 
variable.  The resulting equation is shown in Equation 5.4.  The limits for freezing 
temperature were -21 oC to -40 oC.  For any temperature within that range the 
square of the temperature would be positive while the temperature itself is 
negative.  The coefficient of TF is 0.2 or -0.2 multiplied by the modulus of TF.  
The coefficient of TF2 is 0.00304 and remains positive.  Although TF2 is always 
one order of magnitude higher than TF, the coefficients imply that 0.20TF is 
always going to be one order of magnitude higher than (3.04x10-3)TF2.  As 
0.20TF is negative, a high freezing temperature is required to attain a good cake 
structure. 
 
  
Equation 5.4 Equation showing relationship between cake structure and 
freezing temperature where CS = Cake Structure, T = Temperature and 
subscript F = Freezing stage and k is a constant 
 
The Tg’ of the test material as measured by mDSC was -16 oC (see section 
5.2.2).  The freezing temperature range investigated was between -40 oC and -
21 oC with ramp rates of 1 oC/min.  The samples were held at 5 oC for two hours 
and then the shelf temperature dropped to the set limit.  A low shelf temperature 
would have resulted in faster freezing and consequently smaller ice crystals.  
Smaller crystals lead to smaller pore sizes which thus imply that the ice 
sublimation will take place at a slower rate due to an increased resistance to 
diffusive flow.  As such, if the primary drying settings were particularly forceful 
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(high shelf temperature and low pressure) the high flow of vapour could collapse 
the cake structure.  Therefore, freezing at a higher temperature closer to the Tg’ 
would allow larger ice crystals to form which minimise or prevent this problem. 
 
The other possible cause of cake collapse due to low freezing temperature 
is the rapidity with which the shelf temperature changed at certain settings.  The 
primary drying temperature range was between -21 oC and -11 oC (five degrees 
plus or minus the Tg’) which meant that at a TF at the higher end of its range, the 
difference in shelf temperature between freezing and primary drying was 0 oC to 
10 oC, whereas at the lower end of the freezing range the difference was a 
minimum of 19 oC and a maximum of 29 oC.  Therefore, in an extreme case where 
the freezing temperature was -40 oC and the primary drying temperature was -
11 oC, the smaller ice crystals caused by rapid freezing would result in a low 
sublimation rate which may be insufficient to cool the product and offset the 
higher than Tg’ shelf temperature resulting in cake collapse. 
  
Similarly one can observe that a long primary drying phase decreases the 
likelihood of collapse by ensuring complete sublimation of the free water in the 
ice phase thereby raising the Tg of the solid cake preventing collapse when the 
shelf temperature is raised to secondary drying operating temperatures.  It can 
therefore be concluded therefore that an ideal cycle should avoid drastic shifts in 
shelf temperature and allow longer slower freezing or an annealing stage to 
maximize crystal size and minimize primary drying time. 
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It is not possible to assess the individual impact of the remaining factors 
due to the interactions occurring between them.  For example the 
PD_Pressure*SD_Temp is shown in Table 5.3 to have a high positive impact on 
cake structure.  However using the prediction tool within DesignExpert 7 to 
calculate predictive results using the model equation, the optimum occurs when 
the secondary drying temperature is 0 oC.  This is because SD_temp also impacts 
the cake structure on its own and has a high negative coefficient.  When 
SD_Temp = 0 this cancels out the negative coefficient resulting in a higher cake 
structure number.  
 
5.3.4 Validation of correlation models 
It was necessary to demonstrate that the model equations are capable of 
accurate predictions.  It was further necessary to understand how accurate these 
predictions are.  Five validation experiments were carried out, four using 
operating parameters within the ranges used for developing the model and one 
using operating parameters outside the model to observe how true the model is 
outside the set ranges.  Each experiment was carried out in triplicate and the 
resultant observed vs predicted graph is shown in Figure 5.3. The model also 
accurately predicted cake structure 100% of the time. The observed results 
correlate almost exactly with the predicted results and one can therefore rely on 
the models for designing a process with confidence. The point 10%/3% 
(predicted/observed) was the one anomaly during the validation investigation. 
Here the model was set to predict high moisture content with an acceptable cake 
structure which was pushing the limits of the model as high residual moisture 
content generally results in a collapsed cake. This experiment did not accurately 
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predict the result which suggests that the model may not be dependable when 
pushed to its limits to produce results that are scientifically unlikely to succeed. 
This demonstrates the fact that although DoE is a valuable tool, it cannot and must 
not replace scientific thought and process during an investigation. 
 
Figure 5.3 Oberved vs Predicted plot for residual moisture content. Predicted 
values are shown with corresponding 95% confidence intervals and 
Observed points are shown with standard errors 
5.4 Conclusions 
In industrial processes as has often been said time is money.  The freeze-
drying process itself is a costly process in terms of the energy consumption in 
creating the low temperatures and low pressures, the capital cost of equipment and 
the potential losses as the 99.99% pure product is loaded into one machine where 
failure could mean the loss of millions of pounds of finished product.  It is 
therefore imperative to keep costs down and the process robust. 
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The results of this chapter demonstrate the ability of DoE to optimize and 
understand the lyophilization process. There are other factors to be taken into 
account most notably that of scale. This investigation was carried out in 5 ml vials 
but only involved 10 vials per run. Although industrially the process would still be 
carried out in the same vials the process would be scaled out to several thousand 
vials. Therefore although the models can identify a cycle that would rapidly dry 
the product, the operator has to take into account the limitations of the equipment 
and potential for choked flower at the limits of the condenser (15). 
 
DoE is a powerful tool that, as demonstrated in this investigation, can be 
used to pinpoint optimum process cycles that minimize drying times while 
ensuring a required quality of product is obtained.  However, the user must be 
wary of the impact of the selected ranges and must analyze the results carefully to 
avoid reaching incorrect conclusions.  There definitely exists an interaction 
between formulation and the process cycle, where different excipients respond 
differently to the same conditions.  This investigation and the one in the previous 
chapters allow the user to design a further set of experiments to investigate the 
optimum formulation under the optimum conditions, possibly involving annealing 
to perfect a process which results in a biologically active dry product with an 
acceptable appearance. 
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Chapter 6. Use of DoE Derived Models in Process Validation 
6.1 Introduction 
Although it may appear repetitious, as the experiment detailed within has 
already been detailed in the previous chapter, this chapter looks at the work from 
a different perspective. It is a requirement of an EngD thesis to demonstrate an 
understanding of process validation. It has previously been stated that DoE lends 
itself well to process validation and this chapter highlights an example procedure 
of how DoE can be applied in such a fashion. 
 
Before any therapeutic is allowed into the market it has to be approved by 
a relevant organisation. Examples of such organisations include the Food and 
Drug Administration (FDA) in the USA, the European Medicines Evaluation 
Agency (EMEA) in Europe and the Medicines and Healthcare Regulatory Agency 
(MHRA) in the UK. While the approach and minutiae of these agencies may 
differ slightly in certain areas, the regulatory body will grant approval on 
condition that the product is safe for administration. In order to demonstrate that 
ones product meets this requirement, it is necessary to show a thorough 
understanding of both the therapeutic agent and the process by which it is made.  
 
 The safety and efficacy of the product itself is demonstrated through 
clinical trials. The process must be shown to be sufficiently robust that one can 
show a consistent quality of product is being manufactured. This is done by 
validating the entire process from start to finish. The definition of process 
validation according to the FDA website is: 
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“Establishing documented evidence which provides a high degree of assurance 
that a specific process will consistently produce a product meeting its pre-
determined specifications and quality attributes.” 
 
 In the past this was taken to mean that the engineer had to fix the process 
and no variation from the approved process was acceptable. Recently however, 
the idea of process validation has been focussed more on the end product and on a 
better understanding of the process with an aim to ensure a consistent product. In 
other words, if the process does undergo either deliberate or accidental variation, 
as long as the operator understands the effect of these variations and can 
demonstrate that according to the documented evidence such a change should not 
result in the product not meeting specifications, the batch is acceptable for 
distribution. This is the principle behind Quality by Design (QbD). 
  
 In some ways process validation is a documented sensitivity analysis, the 
operator decides on predetermined limits of acceptability for the product and then 
demonstrates how much variation can take place before the product is 
unacceptable. 
 
 It is a requirement of an EngD thesis that a chapter be devoted to process 
validation. With this in mind the purpose of this investigation was to validate the 
process cycle model developed in Chapter 5 to assess its suitability, sensitivity, 
reliability and limitations. 
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6.2 Materials and Methods 
  The methods and materials used have already been described in section 
5.2.5. 
 
6.3 Results and Discussion 
 Chapter 5 details the development of a product specific model to allow the 
user to predict cake structure and residual moisture content of a freeze dried 
product depending on the freeze drying cycle used. Following development of 
such a model the user would have to validate the model and confirm its accuracy. 
This can be done by inputting various process parameters into the model to get a 
prediction and then carry out the modelled cycle to get actual data. These results 
can be shown in a plot of predicted vs actual moisture content remaining in 5 ml 
vials after freeze-drying, as shown in Figure 5.3. The first important detail to note 
is the standard error bars for the observed points. These points are the results of 
three identical runs and their size indicates the level of consistency the process 
achieves. In general, industrial lyophilization processes aim to achieve less than 
2% residual moisture content (102). The first point in Figure 5.3 shows that not 
only is this possible but even with the standard error the residual moisture is still 
below 2% thus demonstrating that the model is capable of predicting final 
moisture contents to an acceptable standard for validation. 
 
 The second point worthy of note is the fact that four out of the five data 
points lie on the predicted vs observed line. This meant that for 80% of the time, 
the model was nearly 100% accurate, or rather for any prediction below 8%, the 
predictions were always correct. Both of these results are important. If a 
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malfunction or process variability occurs during freeze-dried material production 
such that the vacuum fails, or secondary drying temperatures are not reached, then 
the operator could input the actual values for the lyophilization cycle parameters 
into the model and find out the current moisture content in the vial with a high 
degree of accuracy provided the model does not predict a moisture content above 
8%. Were it to do so, then the model cannot be relied on as the actual moisture 
content could potentially be wholly incorrect. If the prediction gives moisture 
content as less than 8% then assuming the process is still ongoing, one can work 
out what further steps are necessary to result in a product that meets the required 
specifications. While this particular model is only looking at one outcome, 
moisture content, it could be expanded to include all outcomes specified by the 
company. 
 
 This method of modelling using DoE can therefore be used in a quality by 
design (QbD) process which, through real-time modelling, has the potential to 
achieve a form of process analytical technology (PAT). 
 
6.4 Conclusion  
 As process optimisation moves towards quality by design, methods that 
allow for a fully demonstrable understanding of the process will become more 
common. This investigation looked at how a statistically designed experiment 
resulted in a system specific process model that could be used to validate the 
process and demonstrate quality by design. The results showed the model to be 
100% accurate within its limitations but those limitations do not negate the 
validity of the model as long as the user understands where those limitations lie. 
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Based on the derived model the user is able to validate the process, monitor the 
process, conduct sensitivity analysis and trouble shooting. 
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Chapter 7. Conclusion 
7.1 Summary 
In Chapter 1 the current state of the art regarding the lyophilization of 
biopharmaceuticals was discussed. Also, the growing requirement for 
lyophilization as a method of long term storage was discussed and the current 
methods used in process development were described. The conclusions of Chapter 
1 identified the need for a high-throughput systematic and automatable process for 
screening multiple variables, and then optimising a lyophilization process and 
formulation.  
 
 High-throughput automation invariably means the use of the microtitre 
plate format. Robotic liquid-handling systems that work with these plates have 
been around for a number of years and are becoming more common pieces of 
equipment in nearly all laboratories. Furthermore, their extension for use in other 
unit-operation designs has been well documented. In Chapter 2 the the use of 
microwell plates for lyophilization was characterized and the following 
conclusions were drawn: 
 
 - It is possible to freeze dry formulations in microwells. However, the 
edges of the microtitre plate must be trimmed to allow good thermal contact with 
the freeze-dryer shelf. 
 - There is a linear relationship between the area of the ice-wall interface 
and the volume of ice that influences the rate of sublimation during primary 
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drying. Therefore, by identifying the rate of sublimation in a microwell, it is 
possible to predict the rate of sublimation in a vial. 
 
 Having shown that microtitre plates can be used in lyophilization design, 
the next stage was to develop a systematic approach to freeze-drying 
biopharmaceuticals. To tackle this, the lyophilization process design was split into 
two parts: formulation and process. As shall be mentioned in more detail later in 
this Chapter, there is definitely a link between the process cycle and the 
formulation. However, an understanding of each of these factors must be first 
established before looking at how they influence each other. 
 
 Lyophilization formulations are generally worked out empirically based on 
experience and any scientific data available. Quantities and types of excipients are 
picked semi-randomly and a hit and miss approach is used to work out the 
optimum formulation. Chapter 3 and Chapter 4 investigated the use of factorially-
designed experiments combined with microtitre plates to develop a high-
throughput platform technology to identify optimum formulations for preserving 
biological activity during lyophilization. The key conclusions from these 
investigations were as follows: 
 
 - A fractional factorial-screening design followed by a central-composite 
optimisation design will identify key factors and display graphically the windows 
of operation within those factors. 
 - The window of operation is valid both in microwells and in 5ml vials. 
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 - The models produced allow the operator to validate the formulation and 
assess the impact of variations in concentrations. 
 - The number of excipients screened, and the ability to use microtitre 
plates, means this method can be defined as a high-throughput technique. 
 
 Having dealt with formulation development it was necessary to look at 
cycle design. It can be argued that although cycle design has an effect on 
preserving biological activity the dominant factor in preserving activity through 
the cycle is the formulation. Similarly it can be argued that the dominant factor in 
reducing residual moisture content in the final dried product and presenting an 
acceptable cake structure is the cycle design. Therefore, the cycle was assessed in 
terms of cake structure and residual moisture content. It was not possible to 
measure residual moisture content in microwells due to various limitations already 
discussed, and so the investigation in Chapter 5 was carried out in 5 ml vials. This 
limitation does not mean that the procedure outlined in Chapter 5 does not qualify 
as a high-throughput method as each run was carried out using only ten vials, and 
theoretically could have been carried out with less. Automated filling machines 
for vials do exist all the user requires are several small freeze dryers. 
 
 Modelling of lyophilization cycles is a challenge as parameters for factors 
such as cake porosity often have to be assumed. Furthermore, such factors are 
often influenced by the cycle design. For example, a rapid freeze can lead to low 
porosity, whereas an annealing step can introduce larger ice crystals and a higher 
cake porosity. The approach taken in Chapter 5 was to avoid a generic model and 
develop a system specific model. The advantage of such a model is that it allows 
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the operator to demonstrate a detailed knowledge of the system and lends itself 
well to validation. The conclusions drawn were as follows: 
 
 - A factorial design investigation will result in a valid model for a given 
system that can be relied upon for robust cycle design. 
 - The model can be used for process validation to demonstrate a good level 
of quality by design. 
 - The key factors identified by the model correlated well with previous 
work discussed in the literature. 
 
7.2 Implications 
 If lyophilization formulation engineers adopted the strategy proposed 
herein and combined it with a liquid handling system, the number of excipients 
and buffer types that could be screened is limited only by the resultant assay or 
protein characterization technique. Methods for high-throughput protein 
characterization are being developed and the use of one of these methods could 
allow literally thousands of formulations to be screened. In terms of pure 
formulation engineering one would only screen excipients and buffers that are 
likely to work, and that are already used in approved biopharmaceuticals or that 
are generally recognised as safe (GRAS). However, for investigative research it 
would be valuable to screen many formulations for several protein products as it 
is possible that patterns may emerge that would allow more accurate predictions 
in the future while enhancing our understanding of the interactions that take place 
between excipients and protein during lyophilization and subsequent storage. 
Although traditional methods could do the same in terms of single factor effects, 
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the interaction effects that can be identified only through factorial design have to 
date not been investigated fully. An understanding for example of why too much 
PEG and lactose result in a damaged protein is important for furthering our 
understanding of protein interactions. The data gathered from large screens of 
different proteins can be collated into a library which may reveal how different 
classes of proteins respond to different excipients. In short, the potential value is 
huge. 
 
 In the immediate term the value of this platform technology is significant. 
Although hit-and-miss approaches can be successful and make use of experience 
(which is a valuable tool also), and available scientific data, the ability to pass this 
knowledge on to new formulation scientists is limited. The high-throughput 
approaches described in this thesis can be adapted by anyone with a reasonable 
understanding of the process and protein chemistry. It can be applied immediately 
as there is no need for special equipment except perhaps an electric saw to trim 
the edges of the vials. If a formulation exists, this method will find it. 
 
 In terms of cycle design it may not be immediately apparent what the 
value of conducting sixty trial runs adds to using standard cycle design 
engineering. Lyophilization cycles are no longer 5-7 days long, and although they 
are probably still over engineered, this is probably by hours rather than days.  
However, although a cycle can currently be designed, the user will not know at 
any one point how dry the product is. The user will not know what the effect a 
variation has on the process which means the process is set in stone and cannot be 
adjusted ever. Even the use of FTS SMART Freeze DryerTM technology will only 
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tell the user the best cycle to use, it will not provide a model that allows for 
variations. For example, if a production process is moved to a different facility 
with a different dryer that might have a different temperature variation or chamber 
pressure, the user cannot know the impact this has on the process and has to start 
validation from square one. Using the method detailed in Chapter 5 the user can 
make adjustments and cope with variations with confidence in the outcome of 
these changes. 
 
 In both formulation and cycle design the approach investigated throughout 
this thesis allows the user to make the statement “the formulation/process selected 
was selected on the basis of…” as oppose to “the formulation/process selected 
was chosen because it works,” which as regulatory bodies move more towards 
quality by design approaches and encourage operators to be familiar with their 
processes, is a significant contribution to the final stages of process design. 
 
7.3 Further work 
 Chapter 5 looked at basic cycle design to obtain a fundamental model thus 
demonstrating the proof of concept. However, several important factors were kept 
constant. Shelf ramp rates can make a difference to the final product as too fast a 
ramp rate for example can result in product collapse (72, 12, 124). Annealing was 
not investigated at all. Having identified a region of optimum operability it would 
be beneficial to conduct a further investigation looking at the impact of these 
factors. 
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 Chapter 5 was carried out in 5 ml vials despite work in Chapter 2 which 
showed a linear relationship existed between vessels of different dimensions. The 
reason for this was that Chapter 5 was looking at the impact of cycle design on 
residual moisture content which could not be measured in microwells. 
Thermogravimetric analysis involves the heating of small samples of material and 
measures the mass lost. The mass lost is due to the residual moisture evaporating. 
A gas chromatography instrument identifies the released vapours and identifies 
the point at which CO2 is evolved as well as H2O. This is the point at which the 
protein is decomposing and the moisture evolved is due to thermal decomposition 
rather than residual moisture. The device can then work out the percentage 
moisture content in the sample. As the samples are prepared in a nitrogen dry box 
and are very small, it is possible to scrape samples from the microwells into the 
pans and assess moisture content in microwells. This would allow full 
characterization of lyophilization in microwells and enable process engineers to 
predict full scale lyophilization cycles from microwell experiments. As 
microwells hold far smaller quantities of material, several cycles could be 
investigated in the time taken to investigate one cycle at vial scale. This would 
alleviate the issue with factorial designed experiments in terms of the number of 
runs required and the time needed to run them. 
 
 Following such characterization it would then be possible to combine 
cycle and formulation design. There is a definite link between formulation and 
drying cycle, literature already exists regarding mannitol for example and the rate 
at which it must be frozen to prevent vial breakage. The rate of freezing will to a 
degree depend on the formulation as will the morphology of the ice and the 
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existence of crystalline or amorphous regions. The maximum product temperature 
before product collapse during primary drying is dependant on the Tg’ and a 
similar argument can be made for the secondary drying temperature which was 
shown in Chapter 5 to be a key factor. The Tg’ is dependant on the formulation. 
Similarly this thesis has split up the moisture content, cake structure and 
biological activity retention and grouped them into either formulation dependant 
or cycle dependant. In truth the cycle design will impact on final biological 
activity, large ice crystals may crush the protein, a harsh drying stage could 
dehydrate the protein shell and damage it. This can be prevented with the correct 
formulation though, so we see a definite link and potential interaction between 
cycle design, formulation and biological activity. A formulation with a high solid 
content will take longer to dry and may not be able to achieve <1% moisture 
content. 
 
 There is also the long term stability factor which was touched upon in 
Chapter 4 where the optimum formulation for preserving G-CSF activity through 
lyophilization did not successfully preserve activity in long term storage at room 
temperature. Long term stability is dependant both on the formulation and residual 
moisture content. Long term stability is arguably the most important factor as the 
whole purpose of lyophilization in the first place is to provide a long term storage 
solution for unstable biopharmaceuticals. Therefore, while retaining 100% of the 
biological activity through the process is a good start, it is not the final solution to 
the problem the engineer is trying to solve. 
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 It can therefore be said that there is definite value in conducting a 
combined study of formulation and cycle design combined preferably in 
microwells to allow a high throughput study. Perhaps one way to conduct such a 
study would be to do a preliminary screen on formulation and cycle design 
separately to eliminate factors that are totally insignificant. This would reduce the 
number of factors to investigate by a significant amount and make the study more 
manageable. 
 
 The design of a liquid handling system with a built in bank of freeze 
dryers would be the result of such work. The user would be able to input the 
factors he/she wants to investigate and walk away while the robot and software 
conduct a full investigation and present an optimum set of results together with 
sufficient data for quality by design validation. 
 
 According to Genetic Engineering and Biotechnology News (125) 25% of 
the products currently in the biopharmaceutical pipeline will require 
lyophilization and this number is set to increase to 40% over the next five years. 
There is constant and growing pressure on the biopharmaceutical industry to 
provide therapeutics at lower costs to the patient which in turn means pressure on 
process engineers to quickly and efficiently design economically efficient 
processes with a proven efficacy and safety. The work conducted in this thesis 
would allow formulation scientists to conduct final stage process engineering in 
such a manner to provide value both to the industry and the final consumer 
. 
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Chapter 8. Appendix I 
This section details briefly the investigations that were undertaken but 
failed to product a positive result 
 
8.12 The use of electrical conductance to measure primary drying rates 
A miniature probe was developed to measure the electrical conductance of 
a sample in a microwell. The probe was made of platinum and the dimensions 
were: 
 
0.26mm thick 
1.8mm wide 
9.3mm available to fit in microwell (due to spacer) 
2.4mm apart 
The probe was connected via a lead through to an ultra sensitive conductance 
meter 
The solution was 5% by weight lactose and the sample size was 200 µL 
The microwells were Sarstedt 96-well flat bottomed plates 
The shelf temperature is set to -35oC and the tray is frozen in situ for at least an 
hour 
The vacuum is non adjustable and is left to give as hard a vacuum as possible 
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 Initially a Fluke MegaOhmeter was used which utilized 2000 volts to 
generate an output. The results from these experiments are shown in Figure 8.1. 
 
Figure 8.1 Resistance of a 5% lactose sample during freeze drying with an 
initial 15 min equilibriation time 
 However, the presence of such a large voltage meant that arcing occurred 
between the probes and a purple parabolic glow could be observed when the 
system was placed under vacuum. 
 
 An ultra sensitive conductance meter was used instead. Due to the 
sensitivity of the instrument, shielding was necessary to prevent interference. 
Initially the meter was placed in the drying chamber but the due to the battery 
freezing a lead through was built and co – axial cabling used to ensure a the probe 
was adequately shielded. The results from this experiment are shown in Figure 
8.2. 
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Figure 8.2 Conductance of sample during primary drying at two different 
shelf temperatures 
 While initial results looked promising, the same trends were observed over 
time at atmospheric pressure. Obtaining reproducibility was difficult as shown in 
Figure 8.3. 
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Figure 8.3 Repeat experiments measuring the conductance of 5% lactose 
during freeze drying 
It was then observed that the conductance of the material drifted towards zero 
regardless of the pressure in the chamber. Therefore this line of investigation was 
brought to a halt. 
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8.13 The use of an infrared probe to measure the primary drying rate 
Infra red is readily absorbed by water and the Tunable Diode Laser 
Absorption Spectroscopy (TDLAS) system which measures the flow of water 
vapour in the tube between the drying chamber and condenser is an example of 
the use of infra red in freeze drying (147). This experiment aimed to develop a 
miniature probe that would sit on top of a vial or microwell and measure the rate 
of water flowing out of the vessel through the use of an infra red diode and 
receptor. However no fluctuation in the signal was observed during freeze drying 
suggesting the vapour flow was too small to be detectable by such a device. 
 
8.14 The use of an Near Infra Red Spectroscopy (NIRS) probe to measure 
primary drying rates in microwells 
An NIRS probe measured the reflectance of a sample in a microwell 
before and after freeze drying. However there was no discernable difference in the 
traces produced from such a scan. 
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Chapter 9. Appendix II 
This section contains a selection of the raw data used for different 
experiments conducted for this thesis. 
 
 
Table 9.1 Results from microtitre plate uniformity experiment used for 
Figure 3.1. Each well was filled with 200 µL water and partially freeze dried. 
The remaining volume of water was measured using a Hamilton syringe. This 
experiment was conducted in duplicate. 
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Table 9.2 Plate reader data for LDH activity before freeze drying the 
screening investigation formulations detailed in Table 3.1 
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Table 9.3 Plate reader data for LDH activity after freeze drying the screening 
investigation formulations detailed in Table 3.1 
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Table 9.4 Plate reader data for LDH activity before freeze drying the 
optimization investigation formulations detailed in Table 3.2 
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Table 9.5 Plate reader data for LDH activity after freeze drying the 
optimization investigation formulations detailed in Table 3.2 
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Table 9.6 Example of cell count data obtained from G-csf assay. This table 
shows the mean cell counts of one assay conducted on the initial formulation 
screen the recipes for which can be found in Table 4.2. The control was an 
unformulated sample that was not freeze dried 
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Table 9.7 Mass of solid in vials used in Chapter 5 for Karl Fischer Titration. 
The run numbers refer to the cycles shown in Table 5.2 [1/10] 
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Table 9.8 Mass of solid in vials used in Chapter 5 for Karl Fischer Titration. 
The run numbers refer to the cycles shown in Table 5.2 [2/10] 
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Table 9.9 Mass of solid in vials used in Chapter 5 for Karl Fischer Titration. 
The run numbers refer to the cycles shown in Table 5.2 [3/10] 
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Table 9.10 Mass of solid in vials used in Chapter 5 for Karl Fischer Titration. 
The run numbers refer to the cycles shown in Table 5.2 [4/10] 
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Table 9.11 Mass of solid in vials used in Chapter 5 for Karl Fischer Titration. 
The run numbers refer to the cycles shown in Table 5.2 [5/10] 
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Table 9.12 Mass of solid in vials used in Chapter 5 for Karl Fischer Titration. 
The run numbers refer to the cycles shown in Table 5.2 [6/10] 
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Table 9.13 Mass of solid in vials used in Chapter 5 for Karl Fischer Titration. 
The run numbers refer to the cycles shown in Table 5.2 [7/10] 
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Table 9.14 Mass of solid in vials used in Chapter 5 for Karl Fischer Titration. 
The run numbers refer to the cycles shown in Table 5.2 [8/10] 
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Table 9.15 Mass of solid in vials used in Chapter 5 for Karl Fischer Titration. 
The run numbers refer to the cycles shown in Table 5.2 [9/10] 
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Table 9.16 Mass of solid in vials used in Chapter 5 for Karl Fischer Titration. 
The run numbers refer to the cycles shown in Table 5.2 [10/10] 
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Table 9.17 Raw Karl Fischer data for runs detailed in Table 5.2 [1/2] 
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Table 9.18 Raw Karl Fischer data for runs detailed in Table 5.2 [2/2] 
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